

Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View

Jeffrey K. Yao¹⁻³ and Matcheri S. Keshavan^{2,4}

Abstract

Schizophrenia (SZ) is a brain disorder that has been intensively studied for over a century; yet, its etiology and multifactorial pathophysiology remain a puzzle. However, significant advances have been made in identifying numerous abnormalities in key biochemical systems. One among these is the antioxidant defense system (AODS) and redox signaling. This review summarizes the findings to date in human studies. The evidence can be broadly clustered into three major themes: perturbations in AODS, relationships between AODS alterations and other systems (*i.e.*, membrane structure, immune function, and neurotransmission), and clinical implications. These domains of AODS have been examined in samples from both the central nervous system and peripheral tissues. Findings in patients with SZ include decreased nonenzymatic antioxidants, increased lipid peroxides and nitric oxides, and homeostatic imbalance of purine catabolism. Reductions of plasma antioxidant capacity are seen in patients with chronic illness as well as early in the course of SZ. Notably, these data indicate that many AODS alterations are independent of treatment effects. Moreover, there is burgeoning evidence indicating a link among oxidative stress, membrane defects, immune dysfunction, and multineurotransmitter pathologies in SZ. Finally, the body of evidence reviewed herein provides a theoretical rationale for the development of novel treatment approaches. *Antioxid. Redox Signal.* 15, 2011–2035.

Introduction

SCHIZOPHRENIA (SZ) is a major mental disorder that typically strikes in adolescence or early adulthood, and continues throughout the life span (256). Its prevalence is equal across all cultures, and it affects ~1% of the general population worldwide (107, 124). SZ is characterized by a positive syndrome consisting of symptoms such as hallucinations, delusions, and paranoia, as well as a negative syndrome marked by alogia, anhedonia, avolition, and blunted affect (252, 262). SZ has been linked to widespread structural and functional brain alterations, the pathogenesis of which remains poorly understood.

The vast majority of research into the pathogenesis of SZ has thus far focused on the dopamine system. However, evidence for dopaminergic alterations in SZ is largely indirect, and is based on the fact that most antipsychotic medications act as antagonists at the dopamine receptor, particularly D₂ (31, 119, 247). A host of alternative hypotheses regarding the pathophysiology of SZ have therefore been proposed over the

years to conceptualize the pathophysiology of SZ. These include neuronal maldevelopment, impaired neurotransmission, role of viral infections, autoimmune dysfunction, and many others. Although there are a variety of apparently disparate biological findings reported in SZ (110, 141, 236), it is possible that there is etiologic heterogeneity, in which multiple etiological factors converge on a final common pathogenetic pathway (or very few pathways) may mediate the recognizable syndromes of SZ. The issue at hand, therefore, is to identify candidate pathological process(es) that account for the constellation of clinical and biological features in SZ patients.

Free radicals are highly reactive chemical species generated during normal metabolic processes, which in excess can lead to membrane damage. Elaborate antioxidant defense systems exist to protect against oxidative stress. There is increasing evidence of antioxidant defense system (AODS) deficits in SZ (13, 27, 53, 66, 89, 147, 154, 157, 191, 204, 216, 293). Membrane dysfunction can be secondary to free radical-mediated pathology, and may contribute to specific aspects of SZ

¹VA Pittsburgh Healthcare System, Medical Research Service, Pittsburgh, Pennsylvania.

²Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

³Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania.

⁴Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard University, Boston, Massachusetts.




FIG. 1. A schematic diagram linking homeostatic imbalance in antioxidant defense system to pathophysiology in schizophrenia (SZ). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

symptomatology and complications of its treatment. A diagram linking AODS imbalance to SZ pathology is illustrated in Figure 1. Specifically, free radical-mediated abnormalities may contribute to the development of a number of clinically significant consequences, including prominent negative symptoms, tardive dyskinesia, neurological signs, and Parkinsonian symptoms. The aim of this article is to provide a comprehensive review of recent research in antioxidant defense system and its possible role underlying the neuro-pathogenetic mechanism of SZ.

Free radicals

Free radicals are reactive chemical species generated during normal metabolic processes involving oxygen and nitric oxide (Fig. 2), including the mitochondrial electron transfer chain, nicotinamide adenine dinucleotide phosphate-dependent oxidase, and autooxidation of polyunsaturated fatty acids (PUFAs) and catecholamines (90, 221). These free radicals (primarily the reactive oxygen species [ROS], superoxide, and hydroxy radicals) play an important role in membrane lipid peroxidation.

There are multiple pathways leading to excessive free radical generation and subsequent oxidative stress. In addition to the superoxide and hydroxyl radicals, another pathway is the formation of peroxynitrite by a reaction of nitric oxide radical and superoxide radical (Fig. 2). Nitric oxide (NO) can also produce hydroxyl radicals as well as nitrogen dioxide radicals. Nitric oxide is a free radical by its unpaired electron. Since NO radicals cannot produce initiation or propagation reactions, they do not generate free radical chain reactions. However, NO is a unique second messenger molecule that mediates a number of cellular functions, including neurotransmission, neurotoxicity and plasticity, vasodilation, regulation of blood flow, and inhibition of platelet aggregation (22, 105, 174). Elevated NO production has been linked to various neurodegenerative disorders, including Alzheimer's disease (186, 255), multiple sclerosis (94), and Parkinson's disease (19, 81, 103).




FIG. 2. Possible mechanisms involving production and removal of oxygen and nitrogen free radicals in mammalian cells. Molecular oxygen can be converted to superoxide radicals ($O_2^{\cdot-}$) in the presence of xanthine oxidase (XO). Subsequently, superoxide dismutase (SOD) catalyzes the conversion of superoxide radicals to hydrogen peroxide (H_2O_2). Catalase (CAT) and glutathione peroxidase (GSH-Px) convert hydrogen peroxide to water. Glutathione (GSH) is utilized by GSH-Px to yield the oxidized form of glutathione (GSSG), which is converted back to GSH by glutathione reductase (GR). Hydrogen peroxide is susceptible to autooxidation to form hydroxyl radicals (OH^{\cdot}), particularly in the presence of metal catalysts such as iron. In addition, nitric oxide (NO), which is the product of a five-electron oxidation of the amino acid L-arginine, can also produce hydroxyl radicals as well as nitrogen dioxide radical. On the other hand, α -tocopherol (vitamin E) has the ability to inhibit lipid peroxidation as a chain-breaking antioxidant. Vitamin E radicals can be recycled back to their native form by ascorbic acid (vitamin C).

Antioxidant defense system

Biological systems have evolved complex protective strategies against free radical toxicity. Under physiological conditions the potential for free-radical-mediated damage is kept in check by the AODS, which is comprised of a series of enzymatic and nonenzymatic components. The critical antioxidant enzymes include superoxide dismutase (SOD; E.C.1.15.1.6), catalase (CAT; E.C.1.11.1.6), and glutathione peroxidase (GSH-Px; E.C.1.11.1.9). These enzymes act cooperatively at different sites in the metabolic pathway of free radicals (Fig. 2). Hydrogen peroxide produced by SOD is decomposed to water and oxygen by the heme protein, CAT, thereby preventing the formation of hydroxy radicals. Failure of this first-line antioxidant defense may lead to an initiation of lipid peroxidation. Selenium-dependent GSH-Px protects against lipid peroxidation by converting hydrogen peroxide to water, or more critically by converting toxic hydroperoxides to less toxic alcohols. Since SOD, CAT, and GSH-Px are critical to different stages of free radical metabolism, altered activity of one enzyme without compensatory changes in other enzymes may leave the membranes vulnerable to damage. Thus, the differential patterning of the antioxidant enzyme activities may provide important clues to the pathogenetic mechanisms of abnormal free radical metabolism (237).

In addition, the nonenzymatic antioxidant components, which may be equally important in the overall AODS (Fig. 2), consist of molecules that react with activated oxygen species and thereby prevent the propagation of free radical chain reactions. The most common nonenzymatic antioxidant molecules are albumin, uric acid, bilirubin, GSH, ascorbic acid (vitamin C), and α -tocopherol (vitamin E).

Altered AODS in SZ

Oxidative stress is a state when there is a dysequilibrium between pro-oxidant processes and the antioxidant defense system in favor of the former. There are potentially multiple pathological consequences of increased oxidative stress, due to increased free radical production and/or inefficient antioxidant systems (*e.g.*, increased SOD and/or decreased CAT activity), which lead to lipid peroxidation. It has been suggested that increased scavenging activity of SOD in the absence of increased superoxide production can depress free radical-dependent reactions, such as those catalyzed by oxygenases (11), thus resulting in decreased catecholamine production. We review below the literature on AODS supporting a role of oxidative stress in SZ pathology (Table 1).

Decreased individual antioxidants in plasma

Albumin, uric acid, and ascorbic acid substantively contribute (>85%) to the total antioxidant capacity in human plasma (271) largely due to their high concentrations relative to those of other antioxidants in blood, for example, GSH, bilirubin, ascorbic acid (vitamin C), and α -tocopherol (vitamin E).

Proteins. Albumin and bilirubin are both metal-binding proteins with free radical scavenging properties. Albumin inhibits lipid peroxidation by binding copper ions and also serves as a scavenger of both oxygen- and carbon-centered free radicals (71, 238). Bilirubin, though less abundant, is a more efficient antioxidant than albumin. Plasma albumin and total bilirubin are reduced in early and chronic SZ (Table 1). Consequently, urinary excretion of biopyrrins (*i.e.*, oxidative metabolites of bilirubin) is increased. In addition, serum thioredoxin, a redox-regulating protein with antioxidant activity, can be released from cells in response to oxidative stress (183). Increased levels of serum thioredoxin have been shown in first-episode, but not chronic SZ (301).

Earlier studies noted that SZ patients had a significantly higher frequency of hyperbilirubinemia than patients with other psychosis (172, 179). To eliminate the potential confounding effects of liver function, a recent case-control study by Vitek *et al.* (268) demonstrated that serum bilirubin levels were markedly lower in SZ patients with physiological range of liver function tests than those age- and gender-matched controls. These authors suggest that increased bilirubin consumption may be resulted from an increased oxidative stress accompanying SZ.

Uric acid. Uric acid (UA), an endproduct of purine catabolism in humans, is mainly synthesized from adenine- and guanine-based purines by the enzyme xanthine oxidase (Fig. 3). The blood levels of UA depend upon the dietary intake of purines, biosynthesis of UA, and the rate of UA excretion (138, 176). UA is a selective antioxidant that removes superoxide by

preventing the degradation of SOD and subsequently inhibits its reaction with NO to form peroxynitrite (260). UA can also neutralize peroxynitrite (125) and hydroxyl radicals (12, 46) to inhibit protein nitration (192) and lipid peroxidation (181), respectively. UA, *via* astroglia, may protect dopaminergic neurons from glutamate toxicity (60). In addition, UA prevents the propagation of oxidative stress from the extracellular to the intracellular milieu by preserving the integrity of the plasma membrane at the lipid-aqueous interface (87). High K^+ -induced depolarization amplifies neuroprotection provided by UA through a mechanism involving Ca^{2+} elevation and extracellular signal-regulated kinases $\frac{1}{2}$ activation (Fig. 4). Thus, decreased plasma UA may reflect decreased ability to prevent superoxide and peroxynitrite from damaging cellular components (138).

At increased levels, however, UA may also be considered as a marker of oxidative stress (12, 248) due to accumulation of ROS (104). Abnormally high plasma (or serum) UA has been related to cardiovascular disease, gout, hypertension, and renal disease (21, 36, 72, 112, 120), whereas low levels of plasma (or serum) UA have been linked to Alzheimer's disease, multiple sclerosis, optic neuritis, and Parkinson's disease (20, 38, 131, 133, 257). Although some studies have indicated that UA may play a role in the development or progression of such diseases (21, 112, 120, 226, 270), it remains unclear whether an increased UA contributes to the cause or is simply a consequence of these pathologic conditions (138). In short, UA can be served as both anti- and prooxidant in the AODS (Fig. 4). Plasma UA levels are reduced in chronic as well as first-episode neuroleptic-naïve patients with SZ (Table 1).

Vitamins. Ascorbic acid is a biological antioxidant that acts as a chain-breaking scavenger for peroxy radicals and acts synergistically with vitamin E (Fig. 2). Basal ganglia, which are rich in dopamine and glutamate, are also rich in ascorbic acid (188); the antioxidant function of ascorbic acid may thus protect against dopamine- or glutamate-induced neurodegenerative process (214). Both plasma and urinary vitamin C levels are decreased in SZ, relative to normal controls, even after controlling for diet. After vitamin C supplementation for 1 month, group differences were no longer significant (249). Some (44, 234), though not all (263), studies suggest that add-on supplementation of vitamin C may reduce oxidative stress and improve the outcome of SZ. Vitamin C requirements for schizophrenic patients may be higher than for normal subjects because they consumed substantially less antioxidant vitamins (C and E) and dietary fiber than a matched control group (159).

The fat-soluble vitamin E is involved in oxidative metabolism (Fig. 2) and is associated with diseases linked to oxidative stress. Brown *et al.* (23) reported decreased lipid-corrected vitamin E levels in SZ with tardive dyskinesia, relative to healthy controls, but not in patients without dyskinesia. However, there are no antioxidant monotherapy treatment trials for SZ treatment, and such a trial is unlikely to be ever conducted in the absence of demonstrable primary antipsychotic activity of an antioxidant molecule (215).

Reduced total antioxidant status in plasma

Although individual antioxidants play a specific role in the AODS, these antioxidants may act cooperatively *in vivo* to

TABLE 1. ALTERATIONS OF ANTIOXIDANT DEFENSE SYSTEM IN PATIENTS WITH SCHIZOPHRENIA

AODS	SZ population	Source	Findings	References	Implications/comments
<i>Antioxidants</i>					
<i>Proteins</i>					
Albumin, Bilirubin	First-episode, neuroleptic-naive Chronic	Plasma Plasma	Decrease 194, 220 Decrease 194, 268, 275, 290, 292		Increased bilirubin consumption may be secondary to oxidative stress.
Biopyrins	Chronic	Urine	Increase 173		Biopyrins are oxidative metabolites of bilirubin.
Thioredoxin (TRX)	First-episode, neuroleptic-naive	Serum	Increase 301		Serum TRX levels were also positively correlated with positive symptoms of Positive and Negative Syndrome Scale.
					Following antipsychotic treatment, reduced TRX levels may provide us with biochemical index of therapeutic outcome.
UA	First-episode, neuroleptic-naive Chronic, treated	Plasma Plasma	Decrease 219, 284 Decrease 289		The potential for steady formation of antioxidant UA from purine catabolism is altered early in the course of SZ (284). UA and inosine (precursor of UA) may be beneficial in the treatment of oxidative stress related neurodegenerative diseases (60, 97, 144, 229, 241).
<i>Vitamins</i>					
Ascorbic acid	Chronic	Plasma Urine	Decrease 43, 249 Decrease 249		Some (44, 234), though not all (263), studies suggest that add-on supplementation of vitamin C may reduce oxidative stress and improve the outcome of SZ.
Tocopherol	SZ with tardive dyskinesia	Plasma	Decrease 23		Vitamin E levels in plasma were corrected for total lipids.
Glutathione	Untreated Chronic	Plasma Plasma CSF	Decrease 212 Decrease 51 Decrease 54		Adjunctive N-acetyl cysteine, a precursor for GSH synthesis, may provide us with a novel therapeutic intervention targeting GSH Dysregulation in SZ (15, 139).
Free thiols	Chronic Chronic	Prefrontal cortex Postmortem caudate Serum Platelets	Decrease 286 Decrease 101 Decrease 49		
<i>Scavenging enzymes</i>					
Superoxide dismutase	Chronic	Serum RBC Platelets	Increase 43, 75, 137, 306 Increase 1, 169, 217, 289, 305 Decrease 50		
	Chronic, untreated Children, untreated Early course, untreated	Postmortem brain RBC Platelets Blood RBC	Increase 168 Increase 290 Decrease 84 Increase 129 Decrease 177, 212		With progression of the illness, the superoxide dismutase levels may rise as a compensatory response to oxidative stress (177).

(continued)

TABLE 1. (CONTINUED)

AODS	SZ population	Source	Findings	References	Implications/comments
CAT	Treated Untreated	RBC RBC	Decrease 212 Decrease 212		
GSH peroxidase	Chronic, treated Untreated	RBC RBC	Decrease 212 Decrease 1	85, 169, 193, 212	
	Neuroleptic-naive	Plasma Plasma	Increase 307 Increase 307		
<i>NO signaling</i>					
NOS activity	Chronic	Postmortem cerebral cortex Platelets	Decrease 277 Increase 45		In light of inconsistent findings, it is surmised that NO and its metabolites may not be of diagnostic value to distinguish SZ from healthy controls or other brain disorders.
NOS concentration	Chronic	Postmortem cerebellar vermis	Increase 122		
Neuronal NOS expression	Chronic	Postmortem prefrontal cortex	Increase 9		
Neuronal NOS expression	Chronic	Hypothalamus	Decrease 16		
NO	Chronic	Postmortem caudate	Increase 287		
		Serum	Increase 253		
		Plasma	Decrease 140, 184		
		RBC	Increase 96		
NO_2^- , NO_3^-	Chronic	CSF	Decrease 213		
NO_2^-	Chronic	Plasma	Increase 308		
		Plasma	Decrease 279		
		Plasma	Decrease 250		
<i>Lipid peroxidation</i>					
Thiobarbituric acid reactive species (TBARS)	Chronic	Blood	Increase 3, 65, 75, 85, 88, 137, 189, 193, 198, 207, 208, 302		Findings to date suggest that oxidative stress occurs at very early in the course of illness, and independent of treatment. However, few other studies from Scottish SZ Research Group (230) and Skinner <i>et al.</i> (235) do not support the view that increased lipid peroxidation is associated with the SZ <i>per se</i> .
	First-episode, neuroleptic-naive	Plasma	Increase 153		
	Chronic	Platelets	Increase 50		
	SZ with tardive dyskinesia	CSF	Increase 146		
Pentane	Chronic	Breath	Increase 134, 202		
Ethane	Chronic	Breath	Increase 211		
Isoprostanol	Chronic	Urine	Increase 52		
<i>Protein modifications</i>					
3-Nitrotyrosine	Chronic	Plasma	Increase 51		
		Platelets	Increase 49		
4-hydroxynonenal	Chronic	Postmortem anterior cingulate	Increase 269		

CSF, cerebrospinal fluid; GSH, glutathione; NOS, nitric oxide synthase; RBC, red blood cell; SZ, schizophrenia; UA, uric acid.




FIG. 3. Altered purine catabolism in first-episode neuroleptic-naïve patients with SZ. Red arrows indicate shifts toward an increase of xanthosine and a decrease of uric acid productions in first-episode neuroleptic-naïve patients with SZ patients at baseline. Reactions shown with dotted lines represent the salvage pathways, which purine bases can be reutilized resulting in considerably energy saving for the cell. Reprinted with permission from Yao *et al.* (284). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

provide synergistic protection to the organs against oxidative damage. Therefore, it is more meaningful to evaluate AODS by measuring not only the individual levels but also the total antioxidant status (TAS) in plasma. Using a within-subject, on-off haloperidol treatment design, we have reported reduced plasma TAS in SZ compared to normal controls (291). Using a different method, similar reductions of plasma TAS were also shown in drug-free SZ (3, 259) and chronic SZ (267). On the other hand, plasma total oxidant status was not significantly different between SZ and healthy controls (267). It is likely that the alterations in antioxidant functions may be a consequence of changed symptom severity rather than direct effects of antipsychotic drug treatment. Thus, reduced plasma TAS may have pathophysiological significance in SZ, consistent with AODS alterations reported in association with tardive dyskinesia (35), negative symptoms, neurological signs, poor premorbid function, and computed tomography scan abnormalities (293). Taken together, the observed decreases in plasma TAS as well as individual antioxidants suggest an increased risk for oxidative damage in SZ.

GSH deficits

GSH plays an important role in metabolism, transport, redox signaling (Fig. 2), and cellular protection. The reduced form of GSH is the major nonprotein thiol present in virtually all cells. Its reducing and nucleophilic properties protect cells against destructive effects of ROS and free radicals (161). Using ^1H -magnetic resonance spectroscopy (MRS) with double quantum coherence (DQC) filtering and water as an internal standard, Do *et al.* (54) first demonstrated GSH deficits in prefrontal cortex *in vivo* in SZ. Their findings were further supported by reduced GSH levels in cerebrospinal fluid (CSF) of drug-naïve SZ patients, and in plasma of early course or untreated SZ patients (Table 1). Free thiols are also reduced in serum and platelets as well as postmortem caudate in SZ patients (Table 1). Such GSH deficits have been linked to a genetic association between SZ and a GAG trinucleotide




FIG. 4. Dual role of uric acid in the antioxidant defense system. Uric acid can neutralize peroxyntite and hydroxyl radicals to inhibit protein nitration and lipid peroxidation, respectively. At increased levels, however, uric acid may be considered as a marker of oxidative stress due to accumulation of reactive oxygen species. Reprinted with permission from Yao *et al.* (284). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

repeat polymorphism in the catalytic subunit of the glutamate cysteine ligase, the key enzyme for GSH synthesis (53).

Using ^1H -MRS with Point RESolved Spectroscopy sequences and LCModel, Wood *et al.* (276) demonstrated 22% higher levels of GSH in SZ patients than in control subjects. A higher GSH level was more evident in nonresponders to nicotin treatment. These authors suggest that GSH is increased in a compensatory manner. However, the mean percent standard deviation of the fit of their GSH was higher than the recommended 20% (or less), making the spectroscopic measurement of GSH less reliable (209). Berger *et al.* (14) failed to detect GSH level using the standard Point RESolved Spectroscopy sequence with $\text{TE} = 30$, suggesting that the GSH measurement by Wood *et al.* (276) might be an artifact. Recent advances in the MRS study of the AODS were reviewed in details by Matsuzawa and Hashimoto in this Forum (158).

Altered levels of scavenging antioxidant enzymes

Among three key scavenging antioxidant enzymes (Fig. 2), SOD has been the most frequently studied. Increased SOD activities have been reported in serum, red blood cells (RBCs), and in frontal cortex and substantia innominata regions of postmortem brains of SZ patients (Table 1) but not by others (233). Neuroleptic-naïve first-episode schizophreniform and schizophrenic patients show both increased SOD activity (129) and decreased SOD activity (84, 177, 212). It is possible that with progression of the illness, the SOD levels rise as a

compensatory response to oxidative stress (177). On the other hand, GSH-Px activity was found to be lower, relative to normal controls, in neuroleptic-treated chronic SZ, and in drug-free female schizophrenic patients (Table 1). In plasma, Zhang *et al.* (307) have reported increased GSH-Px activities in long-term neuroleptic free as well as neuroleptic-naïve SZ patients, whereas Yao *et al.* (288) did not find any significant difference between chronic SZ and normal subjects, but is correlated with psychosis severity. Further, no differences were found in GSH-Px levels from skin fibroblasts of SZ patients and normal controls (307), suggesting that plasma GSH-Px elevation in patients may be state-dependent changes, and not a consequence of course of illness, treatment effects, or neuroleptics.

Examining individual enzymes may have limited value for elucidating the role of abnormal AODS in disease processes (217). Since SOD, CAT, and GSH-Px are critical to different stages of free radical metabolism, altered activity of one enzyme without compensatory changes in other enzymes may leave membranes vulnerable to damage. Thus, the differential patterning of the antioxidant enzyme activities may provide important clues to the pathogenetic mechanisms of abnormal free radical metabolism (217). Using a within-subject, repeated measures, on-off haloperidol treatment design, we have further evaluated three critical enzymes of the AODS (SOD, CAT, and GSH-Px) in SZ (288, 290). Among the three major AODS enzymes in erythrocytes and plasma, only RBC-SOD was found significantly higher in drug-free SZ patients than in age- and sex-matched normal volunteers (290). Our findings are consonant with most previous reports of increased SOD activity that have been reported in erythrocytes of drug-free and treated SZ patients.

Nitric oxide signaling

NO is the product of a five-electron oxidation of the amino acid L-arginine by nitric oxide synthase (NOS) (195). There are three isoforms of the NOS family: neuronal (nNOS), inducible (iNOS), and endothelial (eNOS) (70). In human brain, nNOS is primarily responsible for the synthesis of NO (18). Under physiologic conditions, NO and its metabolites react with various thiols (*e.g.*, GSH) to form stable S-nitrosothiols (130). These thiol compounds play an important role in the suppression of NO functions in cellular membranes. Previously, Gegg *et al.* (80) have demonstrated an increase of GSH in astrocytes exposed to NO. Thus, to suppress the NO radical function, the level of cytosolic thiol compounds may be elevated in response to an increased NO production (287). The reaction of NO with free thiols may compete with a substrate such as GSH for decomposition of hydrogen peroxide by GSH peroxidase (Fig. 2).

Changes in cellular expression of brain-associated NOS/nicotinamide adenine dinucleotide phosphate diaphorase have been variable in SZ (2). Increased levels of nNOS were found in cerebellar vermis of SZ (Table 1), but no differences in the expression of NOS in cerebellar granule cells (55). Later, Xing *et al.* (277) demonstrated decreased constitutive NOS activity but normal nNOS protein in the cerebral cortex of SZ patients. In addition, increased levels of nNOS mRNA (9) and reduced hypothalamic nNOS expression (16) were also reported in SZ. Utilizing a sensitive fluorometric assay, Yao *et al.* (287) showed an increased NO production independent of

age, brain weight, postmortem interval, sample storage time, alcohol use, or cigarette smoking in postmortem caudate nucleus in SZ. On the other hand, NO metabolites, nitrate and nitrite, were reduced in the CSF samples of SZ patients (213). Peripheral findings have also been inconsistent (Table 1), suggesting that NO and its metabolites may not be of diagnostic values.

Homeostatic imbalance of AODS

GSH redox coupling. The GSH deficiency induced in the animal model has been related to mitochondrial damage (161, 231) and increased free radical insult (5, 185). Moreover, several pathological conditions, including Alzheimer's, Huntington's, and Parkinson's diseases, have been associated with a deficiency of GSH and imbalanced ratio of GSH to oxidized GSH (GSSG) (111, 123). In postmortem caudate region, we (286) have also demonstrated positive correlations between GSH levels and GSH-Px or glutathione reductase (GSH-R) activities in postmortem caudate from control subjects without any psychiatric disorders. Concomitantly, GSH-Px was significantly correlated with GSH-R activities in control subjects (Fig. 5). These positive correlations suggest that a dynamic state regulates the redox coupling under normal conditions. By contrast, lack of such correlations in SZ point to a disturbance of redox coupling mechanisms in the AODS, possibly resulting from a decreased level of GSH as well as age-related decreases of GSSG and GSH-R activities (Fig. 6; for details see subsection Age under section Factors influencing antioxidant status).

A recent integrative review by Do *et al.* (53) posited that redox dysregulation resulting from the convergence between genetic impairments of GSH synthesis and oxidative stress generating environmental insults would lead to hypoactive N-methyl-D-aspartate (NMDA) receptors, impairment of fast-spiking parvalbumin GABA interneurons, and a deficit in myelination. Such a defect in GSH redox signaling not only attenuates deaminase (DA) modulation of calcium responses to NMDA (245) but also affects the structural and functional connectivity in the brain, which may contribute to the development of SZ (244). Following an add-on clinical trial with the GSH precursor and antioxidant N-acetyl-cysteine, both the negative symptoms (15) and the auditory evoked potential (139) were significantly improved in clinically stable patients with chronic SZ. These findings suggest a novel therapeutic intervention targeting GSH dysregulation in SZ.

Purine catabolism. Mitochondria process most of the cellular oxygen to provide energy that drives almost all metabolic processes, and also are the site of significant free radical production. About 3% of all oxygen consumed is converted to superoxide, and subsequently to hydrogen peroxide (69). Thus, there is an enormous and continuous free-radical burden. Antioxidant systems keep this in check. When the equilibrium between pro-oxidant and antioxidant systems are disturbed in favor of the former, mitochondrial damage can occur. Mitochondrial membranes, similar to neuronal membranes, are vulnerable to lipid peroxidation. Any impairment in mitochondrial oxidative phosphorylation can lead to a broad range of cellular disturbances, including decreased neurotransmission, decreased DNA repair, and, finally, cell death. Cytochrome-c oxidase is a key enzyme in the




FIG. 5. Correlations of GSH-Px to glutathione reductase (GSH-R) activities in postmortem caudate region. (A) Control subjects without mental disorders, (B) control subjects with bipolar and/or depression, and (C) patients with SZ. Reprinted with permission from Yao *et al.* (286).

mitochondrial electron transport chain. Decreased activity of this enzyme has been reported in the frontal cortex and caudate nucleus of schizophrenic patients. Several lines of evidence suggest decreased oxidative metabolism in some brain areas in SZ (24, 286, 287), and may be explained in part by mitochondrial dysfunction. We propose that this is secondary to oxidative stress due to decreased antioxidant capacity and/or increased free radical burden.




FIG. 6. Correlations of GSSG or GSH-R activities to age in postmortem caudate region. (A) Control subjects without mental disorders, and (B) patients with SZ. Reprinted with permission from Yao *et al.* (286).

An early study by Kristal *et al.* (136) indicated that purine catabolism may contribute to mitochondrial antioxidant defense by producing UA. Failure to maintain elevated xanthine and UA occurred contemporaneously with progressive mitochondrial dysfunction. Thus, purine catabolism appears to be a homeostatic response of mitochondria to oxidant stress and may protect against progressive mitochondrial dysfunction in certain disease states (136). In response to oxidative stress, decreased energy charge, or nucleic acid damage, purine metabolism shifts to favor breakdown to xanthine and uric acid.

During the *de novo* synthesis of purine nucleotides, many reactions require a great deal of energy utilizing the hydrolysis of adenosine triphosphate. To provide energy saving for the cell, the purine bases can be reutilized *via* salvage pathways (41) by converting adenine, guanine, or hypoxanthine (Hx) to AMP, GMP, or IMP, respectively (shown dotted arrow in Fig. 3). The unsalvaged Hx is then converted to xanthine (Xan), which is further converted to UA by xanthine oxidase. In humans, UA is the final product of purine catabolism (142), which has been implicated as a risk factor and cause of numerous pathological conditions (see below).

Recently, we have evaluated the purine pathway by quantitative determinations of six major purine metabolites consisting of xanthosine (Xant), Xan, Hx, guanine (G), guanosine (Gr), and UA (284). During the purine degradations, both conversions from Gr to G and from Xant to Xan are readily reversible (Fig. 3). Altered ratios of product to precursor, that is, significantly decreased ratios of G/Gr, UA/Gr, and UA/Xant, and the increased ratio of Xant/G, suggested a shift favorable to the Xant formation (approximately twofold increase) in the first-episode neuroleptic-naïve patients with schizophrenia (FENNS). Consequently, the potential for steady formation of UA from purines was reduced at first testing of the patients, which is shown in the red arrow of Figure 3. In addition, there are tightly correlated precursor and product relationships within purine pathways; although some of these correlations persist across disease or medication status, others appear to be lost among FENNS. Taken together,

these results suggest that the potential for steady formation of antioxidant UA from purine catabolism is altered early in the course of SZ and may be independent of treatment effects.

Increased lipid peroxidation and protein modifications

Lipid peroxidation. Changes in antioxidant defense system such as decreased plasma TAS do not necessarily reflect an increased oxidative stress and subsequent membrane lipid damage. While evidence of peroxidative damage is limited to SZ patients, the findings have been consistent. Increased blood levels of malondialdehyde (MDA) were found in SZ patients (Table 1). A similar increase of lipid peroxides was also demonstrated in CSF samples (146) and platelets (50) of SZ patients. In addition, elevated plasma lipid peroxides were also shown at the onset of psychosis in never-medicated, first-episode SZ patients (153), suggesting the presence of oxidative stress at very early in the course of illness, and independent of treatment. Increased concentrations of pentane and ethane, which are other markers of lipid peroxidation, have also been reported in SZ relative to normal controls (Table 1). By contrast, findings from Scottish SZ Research Group (230) and Skinner *et al.* (235) do not support the view that increased lipid peroxidation is associated with the SZ *per se*.

Although the classical determination of MDA by complexation with thiobarbituric acid reactive substances is widely used for assaying lipid peroxides, clinical application is somewhat limited because of concerns relating to analytical specificity, sensitivity, reproducibility, recovery, sample instability, and drug interference (109). One alternative approach is to determine isoprostanes, which are prostaglandin isomers resulting from free radical insult of arachidonic acid (AA) *in situ* on membrane phospholipids (175). Isoprostanes are chemically stable end-products of lipid peroxidation and are excreted in urine (8). The increased plasma MDA levels were supported by a significantly increased excretion of isoprostanes in urine of the same SZ patient individuals as compared to control subjects (52).

Protein modifications. There are high levels of free radicals that are formed by the mitochondrial respiratory chain, with subsequent damage to mitochondrial proteins, DNA, and lipids (182). Protein oxidation is identified as carbonyl formation resulting from ROS, and 3-nitrotyrosine as a marker of reactive nitrogen species. Increased oxidative/nitrative modifications have been demonstrated in both plasma and platelet proteins of SZ patients (Table 1). By application of immunohistochemistry determining 4-hydroxynonenal protein adducts, Wang *et al.* (269) have recently shown that levels of 4-hydroxynonenal (a major product of lipid peroxidation) were also significantly increased in the postmortem anterior cingulate brain from SZ patients. Recent advances in proteomic studies have provided considerable evidence further supporting a role of oxidative stress in SZ (156).

Factors influencing antioxidant status

Age. Previous studies have linked aging process to oxidative injury (58, 73). The balance between free radical production and antioxidant defense system is an important mediator of the mechanism of aging (92). In general, the rate

of oxidative damage by free radicals to membranes provides us an index to determine life span (91, 171, 232). Previously, we have reported that reduction of plasma antioxidant proteins appears to be age related in patients with chronic SZ (292). Contrary to normal control subjects, there was an inverse correlation between plasma albumin and age in SZ. On the other hand, plasma total bilirubin levels were positively correlated with age in normal control subjects, but not in SZ patients. Such age-related correlations were not found in the FENNS and age-matched normal controls (219), perhaps resulting from a narrow range of age (mean age, 28 years; range, 18–40 years) in the FENNS group as compared to the previously reported patients with chronic SZ (mean age, 35 years; range, 18–55 years).

Recently, in the caudate region of postmortem brains, we (286) have further shown that both GSSG and GSH-R levels were significantly and inversely correlated to age of SZ patients, but not control subjects (Fig. 6). However, the plasma AODS enzyme activities were not significantly correlated with subject age, age of onset of illness, or the duration of illness (288, 290). It is likely that decreased levels of GSH result from a decrease of GSH-R in the brain with aging, suggesting an increased susceptibility to oxidative damage with accelerated aging. In addition, several lines of evidence indicate accelerated aging processes in SZ (132). Certain biomarkers of aging, including telomere functioning (68, 121, 205), deficient insulin-like growth factor-1 levels (264), and increased interleukin (IL)-6 levels (206, 282), were also abnormal in SZ patients. Taken together, age appears to be an important factor modifying AODS in SZ.

Antipsychotic drugs. Applying the controlled discontinuation of haloperidol in patients with chronic SZ, we have previously examined the antipsychotic effects on plasma antioxidant status. Neither individual antioxidant levels nor total antioxidant status were significantly affected by antipsychotic treatment (194, 267, 289, 291, 292). More importantly, the altered AODS were observed independent of treatment since patients were antipsychotic drug-naïve at entry into the study (194, 212, 219, 267). Although decrease of plasma uric acid levels were observed in patients after haloperidol withdrawal (289), it is unlikely that the decreased uric acid levels in patients with chronic SZ are due to the antipsychotic effects since the haloperidol treatment was associated with increased uric acid levels within SZ patients. Similarly, neither increased serum nitric oxide levels (253) nor increased lipid peroxidation (75, 193, 302) in SZ patients were affected by antipsychotic treatment. A recent study by Lee and Kim (140) further indicated that plasma NO levels in SZ patients were significantly lower than in normal controls both before and after 6-week treatment with risperidone.

On the other hand, several other studies have shown that blood levels of TAS (3), SOD (43, 306), MDA (3), IL-2 (306), and thioredoxin (301) may be regulated by antipsychotic treatment in SZ patients. Miljevic *et al.* suggested that atypical antipsychotic drugs (*e.g.*, clozapine)-induced metabolic syndrome may be mediated through the oxidative stress mechanisms (169).

In postmortem studies, it is possible that alterations in the GSH redox state are attributable to the long-term treatment with antipsychotic drugs that SZ patients likely received. In our previous study (286), all patients were on antipsychotic

medications at the time of death. No significant differences, however, were shown in the caudate mercaptans between control subjects with or without nonschizophrenic psychiatric disorders. Grima *et al.* (86) have proposed that GSH deficit in SZ may be associated with dopamine-induced oxidative stress. Antipsychotic drugs are known to block DA receptors and, consequently, may result in increased levels of GSH. Therefore, the GSH deficit is unlikely due to antipsychotic effects, because GSH levels may be lower in SZ patients in the absence of antipsychotic treatment.

Data on the effect of antipsychotic drugs on molecular markers are complicated by the lack of complete database on the dose and duration of different antipsychotic drugs taken by the patients. Data from animal model studies have indicated that antipsychotic drugs may have differential effects (time and dose dependent) on molecules in redox signaling (203).

Diet. Diet, caloric intake, and alcohol can affect both the antioxidant system and the production of free radicals (196). Malnutrition can cause low plasma albumin levels (170). In our previous studies examining antioxidant capacity in plasma (289–292, 297), SZ patients were all hospitalized and maintained on a controlled and balanced diet without alcohol consumption. Subsequent studies in FENNS (219), all participants including controls were recruited from the general population, without a controlled diet. In general, patients were not undernourished as indicated by the normal range of body mass indices. Systematically examining the associations between diet, sociodemographic, and physical characteristics in community-dwelling SZ patients, Strassnig *et al.* (246) concluded that SZ patients do not make dietary choices different from those of people in the general population. Thus, dietary factors may not have predominant confounding effects on plasma antioxidant capacity.

Although diet has profound effect on the developing brain, the mature brain is more resistant to undernutrition (82). It is unlikely that diet alone accounts for the findings of AODS defects in SZ patient groups from different countries and different continents.

Cigarette smoke. Cigarette smoke contains many pro-oxidants in both the gas and tar phases, and may contribute directly to oxidative stress and decreases in antioxidants (37, 210). One of the major compounds in the gas phase of tobacco smoke is nitric oxide. It has been suggested that nitric oxide reacts with smoke olefins to form carbon-centered radicals (210). The tar phase consists of a semiquinone radical that promotes hydrogen peroxide formation. Moreover, tobacco smoke may increase free radical formation by activating neutrophils.

On the other hand, several *in vivo* studies have shown antioxidant properties of nicotine (67, 143), which might explain the protective effects of smoking against the development of Parkinson's disease (239). Cigarette smoking by SZ patients exceeds the rates in the general population by 2–3-folds (102, 145, 189). Some investigators have suggested that cigarette smoking in schizophrenic patients may be a method of self-treatment (189) or smoking may serve as a behavioral filler (102), or there may be an underlying neurobiological cause (243). Further, smoking may help to offset the sedative or other adverse effects of psychotropic medications. It has been shown that smoking decreases the blood levels of many psychoactive agents by activating hepatic microsomal en-

zyme systems, thereby increasing their metabolism (102), and may help overcome the dopaminergic blockade and associated medication side effects, including akathisia, drowsiness, dystonia, and Parkinsonism (145). Some, or all, of these factors may underlie the high rates of smoking in schizophrenic patients (218).

Previously, we have shown that cigarette smoking can significantly reduce the levels of plasma bilirubin (292) but not of albumin (219, 292) and uric acid (219, 289). Although bilirubin is a more efficient antioxidant than albumin, the overall contribution of plasma TAS from bilirubin is only <5% as compared to that of >70% from albumin and uric acid (169, 271). Moreover, plasma TAS was not correlated with levels of plasma cotinine (291), which is the major metabolite of nicotine. Recent findings from Ustundag *et al.* (259) also showed significantly lower levels of plasma TAS in medication-free SZ patients independent of smoking habits. Similarly, levels of plasma MDA were significantly higher in chronic SZ patients than in age-, gender-, and smoking-matched healthy control subjects (302). Approximately 68%–70% of subjects were smokers in both patient and control groups. In addition, serum thioredoxin levels were not significantly different between smokers and nonsmokers (301). Taken together, cigarette smoking alone does not appear to be a confounding factor in altering AODS in SZ patients, although increased oxidative stress may be associated more with the smokers than the nonsmokers (230, 259, 304).

Oxidative Stress, Membrane Dynamics, Immune Response, and Neurotransmission

Much of the research focus in SZ has been on neurotransmitter systems. Although the role of dopamine in the pathophysiology of SZ remains preeminent, recent findings suggest instead that multiple neurotransmitter systems may be involved. Whether these are primary or secondary to other pathological processes, such as oxidative stress and membrane dysfunction, will need to be determined in future studies. It is important to recognize, however, that alterations in the metabolism of several neurotransmitter systems can both contribute to, and be modified by oxidative stress (or membrane dysfunction).

Altered phospholipids and PUFAs

Membrane PUFAs highly susceptible to free radical insult. Lipids account for ~50% of the brain's dry weight. Phospholipids in particular constitute 50%–70% of the makeup of brain lipids (251), which contain high levels of PUFAs, most notably AA (n-6) and docosahexaenoic acid (DHA; n-3). PUFAs are highly susceptible to free radical insult and auto-oxidation to form peroxyradicals and lipid peroxide intermediates, the existence of which within cell membranes (Fig. 7) results in unstable membrane structure, altered membrane fluidity and permeability, and impaired signal transduction (62). Hydroperoxides can further decompose to other toxic species (aldehydes, including malonyldialdehyde), which can damage adjacent cells, membrane-bound enzymes, and receptors, cause cross-linking between various types of molecules, and result in membrane breakdown, cytotoxicity, mutagenicity, and enzyme modification (33, 34, 62). Aldehydes can react with lipids and proteins forming lipofuscin,

which accumulates in neuronal cells, particularly in regions of active free radical metabolism.

Thus, the unchecked effects of free radicals can result in cellular dysfunction, loss of membrane integrity, and even cell death. The brain, which is rich in PUFAs, is particularly vulnerable to free-radical-mediated damage.

Abnormal phospholipid metabolism. There are a variety of findings indicative of defects in phospholipid metabolism and cell signaling in patients with chronic SZ as well as in first-episode neuroleptic naïve patients with SZ (59, 151, 236). These findings include (i) decreased PUFAs and altered phospholipids in plasma (98, 115), RBC (7, 83, 118, 128, 187, 199, 220, 296), platelets (77), skin fibroblasts (150, 152), and postmortem brain tissues (98, 160, 227, 285); (ii) increased levels of DHA in CSF (117); (iii) increased turnover of inositol phospholipids (48, 64, 298) and production of second messengers (116, 295); (iv) decreased incorporation of AA in platelets (48, 295); and (v) increased lipid peroxidation in plasma (128, 153), CSF (146, 193) and platelets (50).

Support for central membrane dysregulation in SZ is also derived by *in vivo* ^{31}P MRS techniques, which assay the rela-




FIG. 7. Schematic membrane structure illustrating the key components and their functional role in cell-cell interaction, interaction with environmental factors, and receptor-mediated signal transduction. Membrane model shows the phospholipid bilayer with embedded in it the receptors for neurotransmitters, physiological mediators and growth factors, transporters for ions and nutritional ingredients, and signal transduction machinery. Phospholipid bilayer is made up of four major phospholipids, phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), which are asymmetrically localized, that is, PC predominantly on outer lipid layer and PE, PI, and PS on inner lipid layer. PE, PI, and PS are highly enriched in arachidonic acid (AA) and docosahexaenoic acid (DHA), which are released by receptor-mediated phospholipases (PLAs). AA and DHA, and their metabolic products, diacylglycerol (DAG), inositol polyphosphates (IPPs), and prostaglandins work as second messengers and physiological mediators, including gene modulation, and thus lead to adaptive and maladaptive cellular changes. Reprinted with permission from Mahadik and Yao (151).

tive concentrations of phospholipid precursors and breakdown products, phosphmonoesters, and phosphodiester, respectively (Fig. 8). Using this methodology, Pettegrew *et al.* (200, 201) demonstrated a significant reduction of phosphmonoester and significantly increased levels of phosphodiester in frontal cortices of FENNS as compared to controls. In addition, an increased adenosine triphosphate and decreased inorganic orthophosphate levels were also found in the frontal cortex. Pettegrew and colleagues (201) suggested that changes in membrane phospholipids might be related to molecular changes that precede the onset of clinical symptoms and brain structural changes in SZ, whereas changes in high-energy phosphate metabolism may be state dependent. Other groups (47, 74, 242, 273) also reported similar findings in membrane phospholipid perturbations in both acutely and chronically ill patients. Also, based on ^{31}P MRS findings, Keshavan *et al.* (126, 127) suggested a possible familial basis for membrane phospholipid changes in SZ. Yao *et al.* (294) have shown that ^{31}P MRS and peripheral indices of phospholipid metabolism may be correlated. Given the obvious need for central measures of brain structure and function, these techniques may prove highly valuable in the further explication of the specific phospholipid and fatty acid abnormalities evident in SZ (158).

Taken collectively, there is ample evidence for the existence of membrane phospholipid and fatty acid defects in early course and chronic SZ. It is thus reasonable to hypothesize that increased oxidative stress may be one of the mechanisms responsible for reduction of membrane PUFAs.

PUFAs, immune dysfunction, and oxidative stress

PUFAs and immune response. Both n-6 and n-3 PUFA are involved in the regulation of inflammatory response system. The n-6 PUFAs, particularly AA, have the pro-inflammatory features, since AA is the precursor of pro-inflammatory eicosanoids, prostaglandin E_2 , and leukotriene B_4 and increase production of IL-1, tumor necrosis factor, and IL-6 (93, 240, 254). On the other hand, the n-3 PUFA eicosapentaenoic acid (EPA) and DHA suppress the production of AA-derived eicosanoids, thus having anti-inflammatory and immunosuppressive effects (28, 166). Previous studies on n-3 PUFA-enriched diets (*e.g.*, fish oil) have shown partial replacement of AA by EPA in inflammatory cell membranes and significantly reduce the *ex vivo* production of pro-inflammatory cytokines (28, 61, 63, 108, 166, 240). Therefore, an imbalance of n-6/n-3 PUFAs may result in an increased production of pro-inflammatory cytokines.

Inflammatory response and ROS production. The inflammatory response is intimately connected with oxidative stress *via* free radical generation (57). During inflammatory processes, infiltrating cells can produce large amounts of ROS. In addition being cytotoxic, these ROS also act as important mediators regulating various cellular and immunological processes. Under physiologically relevant concentration, hydrogen peroxide was shown to either increase the production of T-cell growth factor (223) or induce the gene expression of IL-2 (148) and IL-6 (113). The enhancement of IL-2 production was associated with a decrease in the intracellular GSH level (148) and was reversed by the addition of exogenous GSH




FIG. 8. A typical *in vivo* ^{31}P magnetic resonance spectrum from the prefrontal region of a healthy subject. The left panel shows the voxel placement for the spectral acquisition, and the right panel shows the spectrum. The x axis represents the frequency in parts per million (ppm). ATP, adenosine triphosphate; PCr, phosphocreatine; PDE, phosphodiester; Pi, inorganic phosphate; PME, phosphomonoesters. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

(222). Hehner *et al.* (95) have further demonstrated enhancement of T cell receptor signaling by a shift in the intracellular GSH redox state. Above findings thus suggest that the intact immune system requires a delicate balance between antioxidant and prooxidant status (56).

In SZ, the unspecific, innate immune system appears to be overactivated as evident by an increase of monocytes (272) and gamma/delta cells (180), resulting in an increased release of IL-6 (76, 261). By contrast, there is a decreased *in vitro* production of IL-2 (17, 32, 265) as well as decreased production of interferon- γ (6, 224, 272), which suggests that the Th-1 system is underactivated in SZ. Since the Th2 system can produce IL-6, Müller *et al.* (178) suggested an imbalance of adaptive immune system with a shift to the Th2-like immune reactivity in a subgroup of patients with SZ. This subgroup is further characterized by more pronounced negative symptoms and poor outcome (228).

However, data published so far have been inconsistent, which may be the result of differences in assay methodology, sample size, sample handling, diagnostic criteria, and comparison groups (282). In addition, several confounding factors, including age, gender, ethnic background, smoking, alcohol, substance abuse, and antipsychotic treatment may also explain these discrepancies (10). In a recent meta-analysis of 62 cross-sectional studies involving 2298 SZ patients and 1858 healthy volunteers, Potvin *et al.* (206) concluded that SZ patients have increased levels of *in vivo* IL-1 receptor antagonist, soluble IL-2 receptor, and IL-6, and decreased levels of *in vitro* IL-2, establishing an inflammatory syndrome in SZ.

Oxidative stress, immune dysfunction, and membrane defects. A number of putative mechanisms have been identified to explain the decreased PUFA levels in SZ (299), notably increased breakdown of phospholipids and decreased incorporation of AA. Both increased oxidative stress and altered immune function may play a role in an induction of phospholipase activities, for example, phospholipase A₂ (PLA₂) responsible for breakdown of membrane phospholipids (Fig. 9). This association is particularly relevant in relation to phospholipids/PUFA, because AA can be converted to a variety of biologically active eicosanoids that serve as potent messengers in regulating the inflammatory response. Indirect evidence for

a dysregulated inflammatory response in SZ stems from the observation of a negative association between SZ and rheumatoid arthritis (163, 258, 266) and decreased prostaglandin-dependent niacin skin-flushing in SZ (99, 164, 165).

Direct evidence of immune changes in SZ have also come to light, particularly in the activities of several cytokines (*e.g.*, IL-2 and IL-6) known to be abnormal in autoimmune dysfunction (78, 282, 306). Given the diverse physiological function of AA, the specific behavioral symptomatology of SZ is related mostly to the effect of AA changes that regulate neurodevelopment, neurotransmitter homeostasis, second messenger signaling, and neuromodulatory activity in SZ. Hence, in the current conceptualization, AA may be at a nexus point in the cascade leading to the syndrome of SZ (Fig. 9), and represents a common biochemical pathway leading to the highly heterogeneous symptomatology and course of SZ (236).

Neurotransmitters as contributors to free radical burden

Previous studies have shown that dopamine metabolism yields free radicals under normal physiological conditions (40). A number of DA metabolic pathways exist that lead to the generation of hydroxyl radicals (Fig. 10). DA is susceptible to autoxidation when the antioxidant defense system is weak (300). Moreover, the progressive loss of DA triggers an increase in DA turnover in the remaining neurons and facilitates the accumulation of toxic byproducts of DA metabolism. Interestingly, DA-induced toxicity is also mediated through DA actions on the NMDA glutamate receptors (14, 26, 167). There is accumulating evidence that NMDA-mediated excitotoxicity involves free radicals such as superoxide and nitric oxide (42, 197). In fact, antioxidants (*e.g.*, ascorbate and α -tocopherol) protect neurons against glutamate neurotoxicity (39, 149).

Other neurotransmitters, particularly glutamate, can induce other metabolic processes that increase free radical production. Activation of NMDA by glutamate stimulates PLA₂ activity to release AA to act as a second messenger, which in turn can lead to the formation of free radicals (106). Decreased availability of AA, due either to increased PLA₂ activity or lipid peroxidation, can lead to impaired glutamatergic neurotransmission, which has been proposed as a




FIG. 9. A putative model integrating lipid peroxidation, phospholipids turnover, AA signaling, and SZ symptomatology. As shown, several possible mechanisms can lead to increased phospholipid breakdown and AA release, including decreased AA incorporation and increased phospholipase activities (PLA₂ and PLC), possibly resulting from increased oxidative stress and cytokine release. The resulting changes in AA level could then affect more downstream processes, including neurodevelopment *via* growth-associated protein (GAP)-43, neurotransmitter homeostasis, phosphatidylinositol signaling, and neuromodulatory actions of endocannabinoids. It is proposed that the specific behavioral symptomatology of SZ is related mostly to the effect of AA changes on the neurochemistry of deaminase, glutamate release, and circulating levels of the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG). In addition, alterations in AA may also affect the inflammatory response, which can then affect PLA₂ release *via* cytokines, further exacerbating phospholipid turnover and AA release. Hence, in the current conceptualization, AA is at a nexus point in the cascade leading to the syndrome of SZ, and represents a common biochemical pathway leading to the highly heterogeneous symptomatology of psychosis. Reprinted with permission from Skosnik and Yao (236). (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

pathogenetic mechanism in SZ (29, 190). A dopamine-glutamate imbalance has also been implicated in SZ (30). Neuroleptic drugs that block dopamine receptors may also enhance the glutamatergic neurotransmission.

Recently, using a targeted electrochemistry-based metabolomics platform, we have compared metabolic signatures consisting of 13 plasma tryptophan-metabolites simultaneously (Fig. 11) between FENNS patients and healthy controls, and between FENNS at baseline (BL) and 4 weeks after antipsychotic treatment (283). It was noted that conversion of serotonin to *N*-acetylserotonin by serotonin *N*-acetyltransferase may be upregulated in FENNS patients, possibly related to the observed alteration in tryptophan and 5-hydroxyindoleacetic




FIG. 10. Autooxidation and oxidative deamination of dopamine. In the presence of Mn, the auto-oxidation of dopamine produces semiquinones (SQ) and superoxide radicals (O₂^{-•}), as well as H₂O₂, which is readily converted to OH• in the presence of Fe²⁺. On the other hand, the enzymatic oxidation of dopamine by monoamine oxidase (MAO) can also produce H₂O₂ and, subsequently, generate the toxic OH•.

acid correlation. Considering *N*-acetylserotonin as a potent antioxidant (79, 274), such increases in *N*-acetylserotonin might be a compensatory response to increased oxidative stress, implicated in the pathogenesis of SZ.

Clinical Implications

Since the pathophysiology in SZ still remains unclear, understanding the clinical implications of oxidative stress and membrane deficits is also limited. Many of the previously unexplained clinical characteristics of SZ, including high pain tolerance, differences in severity and prognosis across different countries (due to dietary variations), the inverse relationship between SZ and some inflammatory disorders, and the remission of symptoms that occur during high fever, may be explained by membrane phospholipid abnormalities (100, 236). However, to directly link the observed AODS defects with SZ pathogenesis, it is necessary to establish a relationship between the traditional positive/negative symptoms of the disease and the noted aberrations in AODS. While preliminary evidence in this regard has been admittedly correlative, such associations between altered AODS indices and clinical symptoms may provide the building blocks for determining causal relationships and developing novel treatment options.

To date, several laboratories have demonstrated associations between AODS enzymes and symptom severity. In platelets, Buckman *et al.* (25) found that GSH-Px activity was inversely correlated with computed tomographic scan measures of brain atrophy in patients with chronic SZ, specifically nonparanoid SZ with a predominance of negative symptoms. Positive symptoms, however, have been correlated with SOD




FIG. 11. Tryptophan metabolic pathways. The **bolded arrow** indicates that pathway may be upregulated in first-episode neuroleptic-naïve patients with SZ. 1, tryptophan hydroxylase; 2, aromatic L-amino acid decarboxylase; 3, serotonin N-acetyltransferase; 4, 5-hydroxyindole-O-methyltransferase; 5, serotonin N-methyltransferase; 6, monoamine oxidase and aldehyde dehydrogenase; 7, monoamine oxidase; 8, alcohol dehydrogenase; 9, tryptophan 2,3-dioxygenase; 10, formamidase; 11, kynurenine 3-monooxygenase; 12, kynurenine transaminase; 13, kynureninase; 14, 3-hydroxyanthranilate oxygenase. Reprinted with permission from Yao *et al.* (283).

activity (129). Decreased SOD activity is associated with impaired pre-morbid school functioning (177) and tardive dyskinesia (278).

Systematic evaluation of relations between three key scavenging antioxidant enzymes and various psychosis rating scales in drug-free schizophrenic patient groups, both RBC and plasma GSH-Px, was found to be significantly and positively correlated to the Bunney-Hamburg psychosis ratings (BHPR) (288, 293). Such a correlation was present in patients both on and off haloperidol treatment. On the other hand, RBC-SOD activities were inversely and significantly correlated with the BHPR or the Scale for the Assessment of Negative Symptoms (SANS) scores. Later, Zhang *et al.* (305) also demonstrated that blood SOD levels were positively correlated with the Brief Psychiatric Rating Scale (BPRS) and Scale for the Assessment of Positive Symptoms (SAPS) total scores in SZ patients.

In addition, significant inverse correlations between plasma TAS and the SANS were demonstrated in drug-free schizophrenic patients (259, 291). A similar inverse correlation between plasma uric acid and BHPR scale was also demonstrated in schizophrenic patients both on and off haloperidol treatment (289). Moreover, plasma bilirubin levels were significantly lower in the negative subgroup of the SZ patient group (194), whereas SZ patients with higher levels of plasma bilirubin showed higher scores on the positive subscales of the Positive and Negative Syndrome Scale (172).

Recently, Zhang *et al.* (303) have demonstrated that plasma MDA levels were positively correlated with Abnormal Involuntary Movement Scale total score and the SANS in SZ patients with tardive dyskinesia. In addition, serum thiorodoxin was significantly correlated with SAPS (301), and plasma NO levels were negatively correlated with SANS in SZ patients (184). Taken together, above findings suggest that

alterations in AODS enzymes and antioxidant status may be a related to changed symptom severity rather than being direct effects of antipsychotic drug treatment, and further suggest the possibility of therapeutic approaches using currently available treatments (215).

Summary and Future Directions

SZ is a major mental disorder without a clearly identified pathophysiology. A number of putative mechanisms have been proposed to explain the etiopathogenesis and illness presentation of SZ, including abnormal neuronal development, impaired neurotransmission, viral infections *in utero*, autoimmune dysfunction, and many others. Extensive, though fragmentary, findings from neurochemical and neuroendocrine studies of SZ have not provided conclusive evidence for any specific etiologic theory of SZ, perhaps due to etiopathogenetic heterogeneity. However, there exists a point of convergence for many of these theoretical models, one that occurs at the level of the neuronal membrane, which is the site of neurotransmitter receptors, ion channels, signal transduction, and drug effects. Membrane deficits, specifically free radical-mediated, can significantly alter a broad range of membrane functions. There is abundant evidence that alterations in key neurotransmitters can both be modified by and contribute to oxidative stress and membrane dysfunction, suggesting a link among oxidative stress, membrane dysfunction, and multineurotransmitter pathologies in SZ (59, 236, 282).

Research into the pathophysiology of SZ is replete with findings across a large variety of discrete biological systems that in many instances are replicable. It must be assumed that




FIG. 12. Antioxidant defense system involving multiple biochemical pathways. It is surmised that some, or all, of these alterations in purine catabolism, neurotransmission, glutathione redox coupling, glucose phosphorylation, one-carbon metabolism, and nitric oxide synthase activation may contribute to oxidative stress and membrane dysfunction in SZ. Reprinted with permission from Yao and Reddy (281).




FIG. 13. Separation of low-molecular-weight, redox-active compounds by high-pressure liquid chromatography coupled with a Coulometric Multielectrode Array System. (A) Flow rate and mobile phase gradient profile; (B) 16-channel chromatograms obtained by separation of standard mixture in a single column (ESA Meta-250, 5 μ m ODS, 250 \times 4.6 mm ID) under a 150-min gradient elution that ranged from 0% to 20% MPB with a fixed flow rate of 0.5 ml/min (A). The temperature of both cells and column was maintained at 25°C. The Coulometric Multielectrode Array System was set to have increments from 0 to 900 mV in 60 mV steps. Reprinted with permission from Yao and Reddy (281).

these findings in multiple systems in the same disorder are likely linked to each other in meaningful ways, and explicating such relationships will permit a more accurate understanding of the dynamics of the underlying pathology. In this review, defects in the antioxidant system, membrane composition, immune response, and neurotransmission were reported in SZ patients. A recent study by Kale *et al.* (18) reported reduced levels of folic acid and vitamin B₁₂, and increased levels of homocysteine and cortisol in never-medicated SZ patients, further indicating an altered one-carbon metabolism in SZ. Conceptually, these abnormalities can be linked (Fig. 12) but until now there has been no practical way of simultaneously examining these discrete, but interrelated, large systems. Therefore, future studies should focus to identify candidate pathological process(es) that account for the complex constellation of clinical and biological features in SZ.

Novel, powerful, and rapid multidimensional separation and characterization methods, for example, high-pressure liquid chromatography coupled with a 16-channel coulometric multielectrode array system (Fig. 13), can lead to revolutionary changes in our understanding at the molecular level (114, 135, 225, 280, 281). The resolving power of these methods is superior to one-dimensional approaches, enabling the comprehensive metabolic analyses particularly in the targeted biochemical pathways. A metabolomic analytic approach has the potential to yield valuable insights into the likely complex pathophysiological mechanisms that affect multiple metabolic pathways (283, 284), and thereby offer multiple windows of therapeutic opportunities. Examples of such interventions include dietary supplementation with a combination of n-3 PUFAs and antioxidants for treatment of SZ patients, particularly in the early stages of illness (59, 155), and in reducing the risk of progression to psychotic disorder in patients with prodromal symptoms (4), and the use of N-acetyl cysteine, a GSH precursor and antioxidant, in treatment of negative symptoms of SZ. Clearly, the redox signaling hypothesis of SZ offers unique ways of thinking out of the box to develop novel, hypothesis-driven interventions to treat this highly disabling disease.

Acknowledgments

This material is based upon work supported in part by the grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory R&D (Merit Reviews and Senior Research Career Scientist Award), VA Pittsburgh Healthcare System, and National Institute of Health [MH58141 (J.K.Y.), and MH45203 (M.S.K.)]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article. The contents of this article do not represent the views of the Department of Veterans Affairs or the U.S. Government.

References

1. Abdalla DS, Manteiro HP, Olivera JA, and Bechara EJ. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic depressive patients. *Clin Chem* 32: 805–807, 1986.
2. Akyol O, Zoroglu S, Armutcu F, Sahin S, and Gurel A. Nitric oxide as a physiopathological factor in neuropsychiatric disorders. *In Vivo* 18: 377–390, 2004.
3. Al-Chalabi BM, Thanoon IA, and Ahmed FA. Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients. *Neuropsychobiology* 59: 8–11, 2009.
4. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, and Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* 67: 146–154, 2010.
5. Anderson ME. Glutathione: an overview of biosynthesis and modulation. *Chem Biol Interact* 111–112: 1–14, 1998.
6. Arolt A, Rothermund M, Wandinger KP, and Kirchner H. Decreased *in vitro* production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. *Mol Psychiatry* 5: 150–158, 2000.
7. Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, and Ma-

- hadik SP. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. *Biol Psychiatry* 53: 56–64, 2003.
8. Awad JA, Morrow JD, Takahashi K, and Roberts II LJ. Identification of non-cyclooxygenase-derived prostanoid (F2- isoprostane) metabolites in human urine and plasma. *J Biol Chem* 268: 4161–4169, 1993.
 9. Baba H, Suzuki T, Arai H, and Emson PC. Expression of nNOS and soluble guanylate cyclase in schizophrenic brain. *Neuroreport* 15: 677–680, 2004.
 10. Banks RE. Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls. *Crit Rev Clin Lab Sci* 37: 131–182, 2000.
 11. Bartosz G. Commentary on: free radicals and the developmental pathology of schizophrenic burnout. *Integr Psychiatry* 5: 43–44, 1987.
 12. Becker BF. Towards the physiological function of uric acid. *Free Radical Biol Med* 14: 615–631, 1993.
 13. Ben-Shachar D and Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. *Int Rev Neurobiol* 59: 273–296, 2004.
 14. Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, and McGorry PD. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. *Neuropsychopharmacology* 33: 2467–2473, 2008.
 15. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaizt I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, and Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. *Biol Psychiatry* 64: 361–368, 2008.
 16. Bernstein HG, Heinemann A, Krell D, Dobrowolny H, Bielau H, Keilhoff G, and Bogerts B. Hypothalamic nitric oxide synthase in affective disorder: focus on the suprachiasmatic nucleus. *Cell Mol Biol (Noisy-le-grand)* 51: 279–284, 2005.
 17. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, and Weizman A. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. *Biol Psychiatry* 38: 297–302, 1995.
 18. Blum-Degen D, Heinemann T, Lan J, Pedersen V, Leblhuber F, Paulus W, Riederer P, and Gerlach M. Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. *Brain Res* 834: 128–135, 1999.
 19. Bockelmann R, Wolf G, Ransmayr P, and Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. *J Neural Transm* 7: 115–121, 1994.
 20. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, and Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. *Brain* 131: 389–396, 2008.
 21. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, and Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. *Stroke* 37: 1503–1507, 2006.
 22. Bredt DS and Snyder SH. Nitric oxide, a novel neuronal messenger. *Neuron* 8: 3–11, 1992.
 23. Brown K, Reid A, White T, Henderson T, Hukin S, Johnstone C, and Glen A. Vitamin E, lipids, lipid peroxidation products and tardive dyskinesia. *Biol Psychiatry* 43: 863–867, 1998.
 24. Buchsbaum MS, Neuchterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E, Asarnow R, Potkin S, and Guich S. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by Positron Emission Tomography. *Br J Psychiatry* 156: 217–227, 1990.
 25. Buckman TD, Kling A, Sutphin MS, Steinberg A, and Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. *Psychiatry Res* 31: 1–14, 1990.
 26. Cadet JL and Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. *Neurosci Biobehav Rev* 18: 457–467, 1994.
 27. Cadet JL and Lohr JB. Free radicals and the developmental pathology of schizophrenic burnout. *Integr Psychiatry* 5: 40–48, 1987.
 28. Calder PC. Immunoregulatory and anti-inflammatory effects of n-3 polyunsaturated fatty acids. *Braz J Med Biol Res* 31: 467–490, 1998.
 29. Carlsson M and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease. *Trends Neurosci* 13: 272–276, 1990.
 30. Carlsson M and Carlsson A. Schizophrenia a subcortical neurotransmitter imbalance syndrome? *Schizophr Bull* 16: 425–432, 1990.
 31. Carpenter WT Jr. and Buchanan RW. Schizophrenia. *N Engl J Med* 330: 681–690, 1994.
 32. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, and Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behavior. *Prog Neuro-Psychopharmacol Biol Psychiatry* 22: 947–957, 1998.
 33. Chan PH and Fishman RA. Transient formation of superoxide radicals in polyunsaturated fatty acid-induced brain swelling. *J Neurochem* 35: 1004–1007, 1980.
 34. Chan PH, Fishman RA, Longar S, Chen S, and Yu A. Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. *Prog Brain Res* 63: 227–235, 1985.
 35. Chen DC, Xiu MH, Liu H, Zhang BS, Wang Y, Kosten TR, and Zhang XY. Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. *J Psychiat Res* 44: 1111–1112, 2010.
 36. Choi HK, Mount DB, and Reginato AM. Pathogenesis of gout. *Ann Intern Med* 143: 499–516, 2005.
 37. Chow KC. Vitamin E and cigarette smoking-induced oxidative damage. In: *Vitamin E in Health and Disease*, edited by Packer L and Fuchs J. New York: Marcel Dekker, Inc., 1992, pp. 683–697.
 38. Church WH and Ward VL. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. *Brain Res Bull* 33: 419–425, 1994.
 39. Ciani E, Groneng L, Voltattorni M, Rolseth V, Contestabile A, and Paulsen RE. Inhibition of free radical production or free radical scavenging protects from excitotoxic cell death mediated by glutamate in cultures of cerebellar granule cells. *Brain Res* 728: 1–6, 1996.
 40. Cohen G. Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defences. *Ann N Y Acad Sci* 738: 8–14, 1994.
 41. Cory JG. Purine and pyrimidine nucleotide metabolism. In: *Text Book of Biochemistry with Clinical Correlations*, edited by Devlin TM. New York: John Wiley & Sons, 1982, pp. 489–528.
 42. Coyle JT and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262: 689–695, 1993.

43. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, and Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. *Neuropsychobiology* 49: 205–209, 2004.
44. Dakhale GN, Khanzode SD, Khanzode SS, and Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. *Psychopharmacology (Berl)* 182: 494–498, 2005.
45. Das I, Khan NS, Puri BK, Sooranna SR, de Bellerche J, and Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. *Biochem Biophys Res Commun* 212: 375–380, 1995.
46. Davies KJ, Sevanian A, Muakkassah-Kelly SF, and Hochstein P. Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. *Biochem J* 235: 747–754, 1986.
47. Deicken RF, Calabrese G, Merrin EL, Meyerhoff DJ, Dillon WP, Weine MW, and Fein G. ³¹Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. *Biol Psychiatry* 34: 503–510, 1994.
48. Demisch L, Heinz K, Gerbaldo H, and Kirsten R. Increased concentrations of phosphatidylinositol and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypical phasic psychoses. *Prostaglandins Leukot. Essent Fatty Acids* 46: 47–52, 1992.
49. Dietrich-Muszalska A, and Olas B. Modifications of blood platelet proteins of patients with schizophrenia. *Platelets* 20: 90–96, 2009.
50. Dietrich-Muszalska A, Olas B, and Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. *Platelets* 16: 386–391, 2005.
51. Dietrich-Muszalska A, Olas B, Glowacki R, and Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. *Neuropsychobiology* 59: 1–7, 2009.
52. Dietrich-Muszalska A and Olas B. Isoprostenes as indicators of oxidative stress in schizophrenia. *World J Biol Psychiatry* 10: 27–33, 2009.
53. Do KQ, Cabungcal JH, Frank A, Steullet P, and Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. *Curr Opin Neurobiol* 19: 220–230, 2009.
54. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, and Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex *in vivo*. *Eur J Neurosci* 12: 3721–3728, 2000.
55. Doyle CA and Slater P. Application of [3H]L-N(G)-nitroarginine labelling to measure cerebellar nitric oxide synthase in patients with schizophrenia. *Neurosci Lett* 202: 49–52, 1995.
56. Droge W, Mihm S, Bockstette M, and Roth S. Effect of reactive oxygen intermediates and antioxidants on proliferation and function of T lymphocytes. *Methods Enzymol* 234: 135–151, 1994.
57. Droge W. Free radicals in the physiological control of cell function. *Physiol Rev* 82: 47–95, 2002.
58. Droge W. The plasma redox state and ageing. *Ageing Res Rev* 1: 257–278, 2002.
59. du Bois TM, Deng C, and Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 29: 878–888, 2005.
60. Du Y, Chen CP, Tseng CY, Eisenberg Y, and Firestein BL. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. *Glia* 55: 463–472, 2007.
61. Endres S, Meydani SN, Ghobani E, Schindler R, and Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. *J Leukoc Biol* 54: 599–603, 1993.
62. Ernster L. Lipid peroxidation in biological membranes mechanisms and implications. In: *Active Oxygens, Lipid Peroxides, and Antioxidants*, edited by Yagi K. New York, NY: CRC Press, 1993, pp. 1–38.
63. Espersen GT, Grunnet N, Lervang HN, Nielsen GL, Thomsen BS, Faarvang KL, *et al*. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. *Clin Rheumatol* 11: 393–395, 1992.
64. Essali MA, Das I, Bellerche J, and Hirsch SR. The platelet phosphoinositide system in schizophrenia: the effects of neuroleptic treatment. *Biol Psychiatry* 28: 475–487, 1990.
65. Evans DR, Puczkowski PY, Brandsma MJ, Mahadik JS, and Mahadik SP. Elevated plasma lipid peroxides in schizophrenic patients without dementia. *Biol Psychiatry* 39: 588, 1996.
66. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, and Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. *Encephale* 32: 244–252, 2006.
67. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, and Kuschinsky K. Effects of nicotine on hydroxyl free radical formation *in vitro* and on MPTP-induced neurotoxicity *in vivo*. *Naunyn Schmiedebergs Arch Pharmacol* 358: 351–359, 1998.
68. Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, and Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. *Schizophr Bull* 35: 437–442, 2009.
69. Floyd RA. Mitochondrial damage in neurodegenerative disease. In: *Free Radicals in Brain Physiology and Disorders*, edited by Packer L, Hiramatsu M, and Yoshikawa T. San Diego, CA: Academic Press, 1996, pp. 313–329.
70. Forstermann U, Schmidt HHHW, Pollock J, Sheng H, Mitchell JA, Warner TD, Nakane M, and Murad F. Isoforms of nitric oxide synthase: characterization and purification from different cell types. *Biochem Pharmacology* 42: 1849–1857, 1991.
71. Frankel EN. *Lipid oxidation*. Dundee, Scotland: The Oily Press Ltd., 1998.
72. Freedman DS, Williamson DF, Gunter EW, and Byers T. Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. *Am J Epidemiol* 141: 637–644, 1995.
73. Fukagawa NK. Aging: is oxidative stress a marker or is it causal? *Proc Soc Exp Biol Med* 222: 293–298, 1999.
74. Fukuzako H, Fukuzako T, Takeuchi K, Ohbo Y, Ueyama K, Takigawa M, and Fujimoto T. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in temporal lobe and positive symptoms. *Prog Neuro-Psychopharmacol Biol Psychiatry* 20: 629–640, 1996.
75. Gama CS, Salvador M, Andreazza AC, Kapczinski F, and Belmonte-de-Abreu PS. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in

- schizophrenia: a study of patients treated with haloperidol or clozapine. *Prog Neuropsychopharmacol Biol Psychiatry* 30: 512–515, 2006.
76. Ganguili R, Yang Z, Shurin G, Chengappa R, Brar JS, Gubbi AV, and Rabin BS. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. *Psychiatry Res* 51: 1–10, 1994.
 77. Gattaz WF, Schmitt A, and Maras A. Increased platelet phospholipase A₂ activity in schizophrenia. *Schizophr Res* 16: 1–6, 1995.
 78. Caughran F. Immunity and schizophrenia: autoimmunity, cytokines, and immune responses. *Int Rev Neurobiol* 52: 275–302, 2002.
 79. Gavazza MB and Català A. Protective effect of N-acetylserotonin on the nonenzymatic lipid peroxidation in rat testicular microsomes and mitochondria. *J Pineal Res* 37: 153–160, 2004.
 80. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S, and Heales SJR. Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurons: implications for neuroprotection/neurodegeneration? *J Neurochem* 86: 228–237, 2003.
 81. Gerlach M, Blum-Degen D, Lan J, and Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. *Adv Neurol* 80: 239–245, 1999.
 82. Gibson RA, McMurchie EJ, Charnok JS, and Kneebone GM. Homeostatic control of membrane fatty acid composition in the rat after dietary lipid treatment. *Lipids* 19: 942–951, 1984.
 83. Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, and Skinner FS. A red cell membrane abnormality in a sub-group of schizophrenic patients: evidence for two diseases. *Schizophr Res* 12: 53–61, 1994.
 84. Golse B, Debray-Ritzen P, Puget K, and Michelson AM. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. *Nouv Presse Med* 6: 2449, 1977.
 85. Gora D, Sandhya M, Shiv G, and Praveen S. Evaluation of antioxidant deficit in schizophrenia. *Indian J Psychiatry* 50: 16–20, 2008.
 86. Grima G, Benz B, Parpura V, Cuenod M, and Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. *Schizophr Res* 62: 213–224, 2003.
 87. Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, and Michel PP. Protection of mid-brain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. *J Neurochem* 109: 1118–1128, 2009.
 88. Guliaeva NV, Levshina IP, and Obidin AM. Indices of lipid free-radical oxidation and the antiradical protection of the brain—the neurochemical correlates of the development of the general adaptation syndrome. *Zh Vyssh Nerv Deiat* 38: 731–737, 1988.
 89. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, Deppen P, Preisig M, Ruiz V, Steullet P, Tosic M, Werge T, Cuenod M, and Do KQ. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. *Proc Natl Acad Sci U S A* 104: 16621–16626, 2007.
 90. Halliwell B and Gutteridge JMC. Oxygen radicals and the central nervous system. *TINS* 8: 22–26, 1984.
 91. Harman D. Aging and disease: extending functional life span. *Ann N Y Acad Sci* 786: 321–336, 1996.
 92. Harman D. Aging prospects for future increases in the functional life span. *Age* 17: 119–146, 1996.
 93. Hayashi N, Tashiro T, Yammamori H, Takagi K, Morishima Y, Otsubo Y, Sugiura T, Furukawa K, Nitta H, Nakajama N, Suzuki N, and Ito I. Effects of intravenous omega-3 and omega-6 fat emulsion on cytokine production and delayed type hypersensitivity in burned rats receiving total parenteral nutrition. *J Parenter Enteral Nutr* 22: 363–367, 1998.
 94. Heales SJR, Bolanos JP, Stewart VC, Brookes PS, Land JM, and Clark JB. Nitric oxide, mitochondria and neurological disease. *Biochim Biophys Acta* 1410: 215–228, 1999.
 95. Hehner SP, Breikreutz R, Shubinsky G, Unsoeld H, Schulze-Osthoff K, Schmitz ML, and Droge W. Enhancement of t cell receptor signaling by a mild oxidative shift in the intracellular thiol pool. *J Immunology* 165: 4319–4328, 2000.
 96. Herken H, Uz E, Ozyurt H, and Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. *Schizophr Res* 52: 289–290, 2001.
 97. Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, and Spitsin SV. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. *FASEB J* 14: 691–698, 2000.
 98. Horrobin DF, Manku MS, Hillman H, Lain A, and Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. *Biol Psychiatry* 30: 795–805, 1991.
 99. Horrobin DF. Niacin flushing, prostaglandin E and evening primrose oil: a possible objective test for monitoring therapy in schizophrenia. *J Orthomol Psychiatry* 9: 33–34, 1980.
 100. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. *Schizophr Res* 30: 193–208, 1998.
 101. Huang TL, Liou CW, and Lin TK. Serum thiobarbituric acid-reactive substances and free thiol levels in schizophrenia patients: effects of antipsychotic drugs. *Psychiatry Res* 177: 18–21, 2010.
 102. Hughes JR, Hatsukami DK, Mitchell JE, and Dahlgren LA. Prevalence of smoking among psychiatric outpatients. *Am J Psychiatry* 143: 993–997, 1986.
 103. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, and Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. *Neuroscience* 72: 355–363, 1996.
 104. Hyden MR and Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. *Nutr Metab (Lond)* 1: 10, 2004.
 105. Ignarro LJ, Cirino G, Casini A, and Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. *J Cardiovascular Pharmacology* 34: 879–886, 1999.
 106. Iuliano L, Pedersen JZ, Pratico D, Rotilio G, and Violi F. Role of hydroxyl radicals in the activation of human platelets. *Eur J Biochem* 221: 695–704, 1994.
 107. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, and Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. *Psychol Med Monogr Suppl* 20: 1–97, 1992.
 108. James MJ, Gibson RA, and Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am J Clin Nutr* 71: 343S–348S, 2000.
 109. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and per-

- oxidative tissue injury. *Free Radical Biol Med* 9: 515–540, 1990.
110. Javitt DC and Laruelle M. Neurochemical theories. In: *Text Book of Schizophrenia*, edited by Lieberman JA, Stroup TS, and Perkins DO. Washington, DC: The American Psychiatric Publishing, 2006, pp. 85–116.
 111. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu R-M, Forman HJ, and Andersen JK. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity, implications for Parkinson's disease. *J Biol Chem* 275: 26096–26101, 2000.
 112. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, Galasso R, Mancini M, and Trevisan M. Serum uric acid and hypertension: the Olivetti heart study. *J Hum Hypertens* 8: 677–681, 1994.
 113. Junn E, Lee NL, Ju HR, Han SH, Im JY, Kang HS, Lee TH, Bae YS, Ha KS, Rhee SG, and Choi I. Requirement of hydrogen peroxide generation in TGF- β 1 signal transduction in human lung fibroblast cells: involvement of hydrogen peroxide in Ca²⁺ + in TGF- β 1-induced IL-6 expression. *J Immunology* 165: 2190–2197, 2000.
 114. Kaddurah-Daouk R, Kristal BS, and Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. *Ann Rev Pharmacol Toxicol* 48: 653–683, 2008.
 115. Kaiya H, Horrobin DF, Manku MS, and Fisher NM. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. *Biol Psychiatry* 30: 357–362, 1991.
 116. Kaiya H, Nishida A, Imai A, Nakashima S, and Nozawa Y. Accumulation of diacylglycerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis? *Biol Psychiatry* 26: 669–676, 1989.
 117. Kale A, Joshi S, Naphade N, Sapkale S, Raju MS, Pillai A, Nasrallah H, and Mahadik SP. Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients. *Schizophr Res* 98: 295–301, 2008.
 118. Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, and Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. *Psychiatry Res* 175: 47–53, 2010.
 119. Kane JM and Marder SR. Psychopharmacologic treatment of schizophrenia. *Schizophr Bull* 19: 287–302, 1993.
 120. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, and Johnson RJ. A role for uric acid in the progression of renal disease. *J Am Soc Nephrol* 13: 2888–2897, 2002.
 121. Kao H-T, Cawthon RM, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, and Porton B. Rapid telomere erosion in schizophrenia. *Mol Psychiatry* 13: 118–119, 2008.
 122. Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM, Snyder SH, Moore NC, and WQ Sturmer. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. *Mol Chem Neuropathol* 27: 275–284, 1996.
 123. Keelan J, Allen NJ, Antcliffe D, Pal S, and Duchon MR. Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane. *J Neurosci Res* 66: 873–884, 2001.
 124. Keith SJ, Regier DA, and Rae DS. Schizophrenic disorders. In: *Psychiatric Disorders in America, the Epidemiologic Catchment Area Study*, edited by Robins LN and Regier D. New York: Free Press, 1991, pp. 33–52.
 125. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB, and Mattson MP. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. *J Neurosci* 18: 687–697, 1998.
 126. Keshavan MS, Stanley JA, Montrose DM, Minschew NJ, and Pettegrew JW. Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: an *in vivo* ³¹P MRS study. *Mol Psychiatry* 8: 316–323, 2003.
 127. Keshaven MS, Pettegrew JW, and Ward R. Are membrane phospholipid changes in schizophrenia familial? *Biol Psychiatry* 33: 45A, 1993.
 128. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, and Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. *Schizophr Res* 58: 1–10, 2002.
 129. Khan NS and Das I. Oxidative stress and superoxide dismutase in schizophrenia. *Biochem Soc Transact* 25: 418S, 1997.
 130. Kharitonov SA, Robbins RA, Yates D, Keatings V, and Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. *Am J Respiratory Critical Care Med* 152: 609–612, 1995.
 131. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, and Lee CU. Decreased plasma antioxidants in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 21: 344–348, 2006.
 132. Kirkpatrick B, Messias E, Harvey PD, Fernandez-Egea E, and Bowie CR. Is schizophrenia a syndrome of accelerated aging? *Schizophr Bull* 34: 1024–1032, 2008.
 133. Knapp CM, Constantinescu CS, Tan JH, McLean R, Cherryman GR, and Gottlob I. Serum uric acid levels in optic neuritis. *Mult Scler* 10: 278–280, 2004.
 134. Kovaleva ES, Orlov ON, Tsutsul'kovskia MIA, Vladimirova TV, and Beliaev BS. Lipid peroxidation processes in patients with schizophrenia. *Zh Nevropatol Psikiatr* 89: 108–110, 1989.
 135. Kristal BS, Shurubor YI, Kaddurah-Daouk R, and Matson WR. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. *Methods Mol Biol* 358: 159–174, 2007.
 136. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, and Matson WR. Purine catabolism: links to mitochondrial respiration and antioxidant defenses? *Arch Biochem Biophys* 370: 22–33, 1999.
 137. Kunz M, Gama CS, Andreatza AC, Salvador M, Cereser KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, and Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 32: 1677–1681, 2008.
 138. Kutzling MK and Firestein BL. Altered uric acid levels and disease states. *J Pharm Exp Therapeutics* 324: 1–7, 2007.
 139. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuenod M, Buclin T, and Do

- KQ. Glutathione precursor, *N*-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. *Neuropsychopharmacology* 33: 2187–2199, 2008.
140. Lee BH and Kim YK. Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. *Schizophr Res* 104: 36–43, 2008.
 141. Lieberman JA and Koreen AR. Neurochemistry and neuroendocrinology of schizophrenia, a selective review. *Schizophr Bull* 19: 371–429, 1993.
 142. Linden J and Rosin DL. Purinergic system. In: *Basic Neurochemistry, Molecular, Cellular and Medical Aspects* (7th edition), edited by Siegel GJ, Albers RW, Brady ST, and Price DL. Boston: Elsevier, 2006, pp. 303–316.
 143. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, and Arendash GW. *In vitro* and *in vivo* studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. *Biochim Biophys Acta* 1454: 143–152, 1999.
 144. Liu F, You SW, Yao LP, Liu HL, Jiao XY, Shi M, Zhao QB, and Ju G. Secondary degeneration reduced by inosine after spinal cord injury in rats. *Spinal Cord* 44: 421–426, 2006.
 145. Lohr JB and Flynn K. Smoking and schizophrenia. *Schizophr Res* 8: 93–102, 1992.
 146. Lohr JB, Kuczenski R, Bracha HS, Moir M, and Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. *Biol Psychiatry* 28: 535–539, 1990.
 147. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. *Arch Gen Psychiatry* 48: 1097–1106, 1991.
 148. Los M, Droge W, Stricker K, Baeuerle PA, and Schulze-Osthoff K. Hydrogen peroxide as a potent activator of T lymphocyte functions. *Eur J Immunol* 25: 159–165, 1995.
 149. MacGregor DG, Higgins MJ, Jones PA, Maxwell WL, Watson MW, Graham DI, and Stone TW. Ascorbate attenuates the systemic kainate-induced neurotoxicity in the rat hippocampus. *Brain Res* 727: 133–144, 1996.
 150. Mahadik SP, Mukherjee S, Correnti E, Kelkar HS, Wakade CG, Costa RM, and Scheffer R. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naïve patients at the onset of psychosis. *Schizophr Res* 13: 239–247, 1994.
 151. Mahadik SP and Yao JK. Phospholipids in schizophrenia. In: *Textbook of Schizophrenia*, edited by Lieberman JA, Stroup TS, and Perkins DO. Washington, DC: The American Psychiatric Publishing, Inc., 2006, pp. 117–135.
 152. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, and Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. *Psychiatry Res* 63: 133–142, 1996.
 153. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, and Mahadik JS. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. *Biol Psychiatry* 43: 674–679, 1998.
 154. Mahadik SP, Parikh V, and Khan MM. The role of oxidative stress in modulating membrane and phospholipid function in schizophrenia. In: *Phospholipid Spectrum Disorders in Psychiatry and Neurology*, edited by Peet M, Glen I, and Horrobin D. Carnforth, UK: Marius Press, 2003, pp. 277–288.
 155. Mahadik SP, Pillai A, Joshi S, and Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. *Int Rev Psychiatry* 18: 119–131, 2006.
 156. Martins-de-Souza D, Harris LW, Guest PC, and Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. *Antioxid Redox Signal* 15: 2067–2079, 2011.
 157. Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, Fujita Y, and Lyo M. Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. *Am J Med Genet B Neuropsychiatr Genet* 150B: 86–94, 2009.
 158. Matsuzawa D and Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. *Antioxid Redox Signal* 15: 2057–2065, 2011.
 159. McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J, and Paterson J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. *Brit Med J* 317: 784–785, 1998.
 160. McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, and Stanford KE. Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medication. *Schizophr Res* 91: 37–50, 2007.
 161. Meister A. Mitochondrial changes associated with glutathione deficiency. *Biochim Biophys Acta* 1271: 35–42, 1995.
 162. Meister A. Selective modification of glutathione metabolism. *Science* 220: 472–477, 1983.
 163. Mellsop GW. Schizophrenia and rheumatoid arthritis. *Aust N Z J Psychiatry* 6: 214, 1972.
 164. Messamore E, Hoffman WF, and Yao JK. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. *Schizophr Res* 122: 248–256, 2010.
 165. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. *Prostaglandins Leukot Essent Fatty Acids* 69: 413–419, 2003.
 166. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morill-Labrode A, Dinarello CA, and Gorbach SL. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. *J Nutr* 121: 547–555, 1991.
 167. Michel PP and Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. *J Neurosci Res* 76: 428–435, 1990.
 168. Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, Weijers HG, and Koutsilieri E. Cu, Zn-, and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. *J Neural Transm* 111: 1191–1201, 2004.
 169. Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, Lecic-Tosevski D, and Spasic MB. Lipid status, antioxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry* 34: 303–307, 2010.
 170. Millward DJ. Protein deficiency, starvation and protein metabolism. *Proc Nutr Soc* 38: 77–88, 1979.
 171. Miquel J, Economos AC, Fleming J, and Johnson JE Jr. Mitochondrial role in cell aging. *Exp Gerontol* 15: 575–591, 1998.
 172. Miyaoka T, Seno H, Itoga M, Iigima M, Inagaki T, and Horiguchi J. Schizophrenia-associated idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). *J Clin Psychiatry* 61: 868–871, 2000.
 173. Miyaoka T, Yasukawa R, Yasuda H, Shimizu M, Mizuno S, Sukegawa T, Inagaki T, and Horiguchi J. Urinary excretion

- of biopyrrins, oxidative metabolites of bilirubin, increases in patients with psychiatric disorders. *Eur Neuropsychopharmacol* 15: 249–252, 2005.
174. Moncada S, Palmer RMJ, and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacology Rev* 43: 109–142, 1991.
 175. Morrow JD, Awad JA, Boss HJ, Blair IA, and LJ Roberts II. Non-cyclooxygenase-derived prostanoids (F₂-isoprostanes) are formed *in situ* on phospholipids. *Proc Natl Acad Sci U S A* 89: 10721–10725, 1992.
 176. Mount DB, Kwon CY, and Zandi-Nejad K. Renal urate transport. *Rheum Dis Clin North Am* 32: 313–331, 2006.
 177. Mukherjee S, Mahadik SP, Scheffer R, Correnti EE, and Kelkar H. Impaired antioxidant defense at the onset of psychosis. *Schizophr Res* 19: 19–26, 1996.
 178. Müller N, Riedel M, Ackenheil M, and Schwarz MJ. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. *World J Biol Psychiatry* 1: 173–179, 2000.
 179. Müller N, Schiller P, and Ackenheil M. Coincidence of schizophrenia and hyperbilirubinemia. *Pharmacopsychiatry* 24: 225–228, 1991.
 180. Müller N, Schlesinger BC, Hadjamu M, Riedel M, Schwarz M, Primbs J, Ackenheil M, Wank R, and Gruber R. Cytotoxic gamma/delta cells (γ/δ CD8+) are elevated in unmedicated schizophrenic patients and related to the Blood-Brain Barrier and the HLA allele DPA 02011. *Schizophr Res* 12: 69–71, 1998.
 181. Muraoka S and Miura T. Inhibition by uric acid of free radicals that damage biological molecules. *Pharmacol Toxicol* 93: 284–289, 2003.
 182. Murray J, Oquendo CE, Willis JH, Marusich MF, and Capaldi RA. Monitoring oxidative and nitrative modification of cellular proteins; a paradigm for identifying key disease related markers of oxidative stress. *Adv Drug Deliv Rev* 60: 1497–1503, 2008.
 183. Nakamura H. Thioredoxin and its related molecules: update 2005. *Antioxid Redox Signal* 7: 823–828, 2005.
 184. Nakano Y, Yoshimura R, Nakano H, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Ueda N, and Nakamura J. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. *Hum Psychopharmacol* 25: 139–144, 2010.
 185. Navarro J, Obrador E, Pellicer JA, Aseni M, Vina J, and Estrela JM. Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. *Free Radic Biol Med* 22: 1203–1209, 1997.
 186. Norris PJ, Faull RL, and Emson PC. Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. *Mol Brain Res* 41: 36–49, 1996.
 187. Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, J Masliah J, and Wolf C. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. *Psychiatry Res* 169: 91–96, 2009.
 188. Oke AF, May L, and Adams RN. Ascorbic acid distribution patterns in human brain. *Ann New York Acad Sci* 498: 1–12, 1987.
 189. Olincy A, Young DA, and Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. *Biol Psychiatry* 42: 1–5, 1997.
 190. Olney JW and Farber NB. Glutamate receptor dysfunction and schizophrenia. *Arch Gen Psychiatry* 52: 998–1007, 1995.
 191. Othmen LB, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, and Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. *Prog Neuropsychopharmacol Biol Psychiatry* 32: 155–159, 2008.
 192. Pacher P, Beckman JS, and Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 87: 315–424, 2007.
 193. Padurariu M, Ciobica A, Dobrin I, and Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. *Neurosci Lett* 479: 317–320, 2010.
 194. Pae CU, Paik IH, Lee C, Lee SJ, Kim JJ, and Lee CU. Decreased plasma antioxidants in schizophrenia. *Neuropsychobiology* 50: 54–56, 2004.
 195. Palmer RMJ, Ashton DS, and Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature* 333: 664–666, 1988.
 196. Papas AM. Determinants of antioxidant status in humans. *Lipids* 31: S77–S82, 1996.
 197. Patel M, Day BJ, Crapo JD, Fridovich I, and McNamara JO. Requirement for superoxide in excitotoxic cell death. *Neuron* 16: 345–355, 1996.
 198. Peet M, Laugharne J, Rangarajan N, and Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. *Intl Clin Psychopharmacology* 8: 151–153, 1993.
 199. Peet M, Laugharne JDE, Mellor J, and Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. *Prostaglandins Leukot Essent Fatty Acids* 55: 71–75, 1996.
 200. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, and Allen M. Alterations in brain high energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. *Arch Gen Psychiatry* 48: 563–568, 1991.
 201. Pettegrew JW, Keshaven MS, and Minshew NJ. ³¹P nuclear magnetic resonance spectroscopy: neuro-development and schizophrenia. *Schizophr Bull* 19: 335–353, 1993.
 202. Phillips M, Sabas M, and Greenberg J. Increased pentane and carbon disulfide in the breath of patients with schizophrenia. *J Clin Pathol* 46: 861–864, 1993.
 203. Pillai A, Parikh V, Terry Jr AV, and Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. *J Psychiatr Res* 41: 372–386, 2007.
 204. Pillai A, Reddy R, and Yao JK. Oxidative stress in schizophrenia. In: *Fatty Acids and Oxidative Stress in Neuropsychiatric Disorders*, edited by Reddy R and Yao JK. New York: Nova Biochemical Books, 2007, pp. 29–42.
 205. Porton B, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM, Greenberg WM, and Kao H-T. Telomerase levels in schizophrenia: a preliminary study. *Schizophr Res* 106: 242–247, 2008.
 206. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, and Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. *Biol Psychiatry* 63: 801–808, 2008.
 207. Prilipko LL and Lideman RR. Lipid peroxidation processes as one of the factors modifying neuronal membrane-bound proteins in schizophrenia. *Vestn Akad Med Nauk SSSR* 1: 33–37, 1982.

208. Prilipko LL. The possible role of lipid peroxidation in the pathophysiology of mental disorders. In: *Free Radicals in the Brain*, edited by Packer L, Prilipko L, and Christen Y. Berlin: Spinger-Verlag, 1992, pp. 146–152.
209. Provencher SW. LCMModel and LCMgui User's Manual. Available at <http://s-provencher.com/pages/lcm-manualshtml>, 2001.
210. Pryor WA and Stone K. Oxidants in cigarette smoke. *Ann N Y Acad Sci* 686: 29, 1992.
211. Puri BK, Counsell SJ, Ross BM, Hamilton G, Bustos MG, and Treasaden IH. Evidence from *in vivo* 31-phosphorus magnetic resonance spectroscopy phosphodiesterases that exhaled ethane is a biomarker of cerebral n-3 polyunsaturated fatty acid peroxidation in humans. *BMC Psychiatry* 8: S2, 2008.
212. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, and Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry* 33: 1178–1183, 2009.
213. Ramirez J, Garnica R, Boll MC, Montes S, and Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. *Schizophr Res* 68: 357–361, 2004.
214. Rebec GV. Ascorbate: an antioxidant neuroprotectant and extracellular neuromodulator. In: *Metals and Oxidative Damage in Neurological Disorders*, edited by Connor JR. New York: Plenum Press, 1997, pp. 149–173.
215. Reddy R and Reddy R. Antioxidant therapeutics in schizophrenia. *Antioxid Redox Signal* 15: 2047–2055, 2011.
216. Reddy R and Yao JK. Free radical pathology in schizophrenia: a review. *Prostaglandins Leukot Essent Fatty Acids* 55: 33–43, 1996.
217. Reddy R, Sahebarao MP, Mukherjee S, and Murthy JN. Enzymes of the antioxidant system in chronic schizophrenic patients. *Biol Psychiatry* 30: 409–412, 1991.
218. Reddy RD, and Yao JK. Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. *Prostaglandins Leukot Essent Fatty Acids* 69: 385–391, 2003.
219. Reddy RD, Keshavan MS, and Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. *Schizophr Res* 62: 205–212, 2003.
220. Reddy RD, Keshavan MS, and Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first-episode schizophrenia at neuroleptic-naïve baseline. *Schizophr Bull* 30: 901–911, 2004.
221. Rice-Evans CA. Formation of free radicals and mechanisms of action in normal biochemical processes and pathological states. In: *Free Radical Damage and Its Control*, edited by Rice-Evans CA and Burdon RH. Amsterdam: Elsevier, 1994, pp. 131–153.
222. Roth S and Droge W. Regulation of interleukin-2 production, interleukin 2 mRNA expression and intracellular glutathione levels in *ex vivo* derived T lymphocytes by lactate. *Eur J Immunol* 21: 1933–1937, 1991.
223. Roth S and Droge W. Regulation of T-cell activation and T-cell growth factor (TCGF) production by hydrogen peroxide. *Cell Immunol* 108: 417–424, 1987.
224. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, and Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. *Neuropsychobiology* 37: 186–193, 1998.
225. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr., and Kaddurah-Daouk R. Metabolomic analysis and signatures in motor neuron disease. *Metabolomics* 1: 101–108, 2005.
226. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, and Kato E. Serum uric acid and the renin-angiotensin system in hypertension. *J Am Geriatr Soc* 26: 241–247, 1978.
227. Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, and Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. *Biol Psychiatry* 56: 41–45, 2004.
228. Schwarz MJ, Muller N, Riedel M, and Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. *Med Hypotheses* 56: 483–486, 2001.
229. Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, and Hooper DC. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. *Proc Natl Acad Sci U S A* 99: 16303–16308, 2002.
230. Scottish Schizophrenia Research Group. Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. *Brit J Psychiatry* 176: 290–293, 2000.
231. Seaton TA, Jenner P, and Marsden CD. Mitochondrial respiratory enzyme function and superoxide dismutase activity following brain glutathione depletion in the rat. *Biochem Pharmacol* 52: 1657–1663, 1996.
232. Shigenaga MK, Hagen T, and Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci U S A* 91: 10771–10778, 1994.
233. Sinet PM, Debray Q, Carmagnol F, Pelicier, Y, Nicole A, and Jerome H. Normal erythrocyte SOD values in two human diseases: schizophrenia and cystic fibrosis. In: *Oxy Radicals and Their Scavenger Systems, Cellular and Medical Aspects. Vol. II*, edited by Greenwald RA and Cohen G. New York: Elsevier, 1983, pp. 302–304.
234. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, and Sarandol E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. *Prog Neuropsychopharmacol Biol Psychiatry* 31: 1493–1499, 2007.
235. Skinner AO, Mahadik SP, and Garver DL. Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia. *Schizophr Res* 76: 83–87, 2005.
236. Skosnik PD and Yao JK. From phospholipid and fatty acid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? *Prostaglandins Leukot Essent Fatty Acids* 69: 367–384, 2003.
237. Smith CV. Free radical mechanisms of tissue injury. In: *Free Radical Mechanisms of Tissue Injury*, edited by Moslen MT and Smith CV. Boca Raton, FL: CRC Press, 1992, pp. 1–22.
238. Soriani M, Pietraforte D, and Minetti M. Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. *Arch Biochem Biophys* 312: 180–188, 1994.
239. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Lopez-Real AM, and Labandeira-Garcia JL. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease. *Biochem Pharmacol* 64: 125–135, 2002.
240. Soyland E, Lea T, Sandstand B, and Drevon A. Dietary supplementation with very long-chain n-3 fatty acids in

- man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with inflammatory skin disease. *Eur J Clin Invest* 24: 236–242, 1994.
241. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, and Koprowski H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. *Mult Scler* 7: 313–319, 2001.
 242. Stanley JA, Williamson PC, Drost DJ, Carr T, Rylett J, Morrison-Stewart S, and Thompson RT. Membrane phospholipid metabolism and schizophrenia: an *in vivo* 31P-MR spectroscopy study. *Schizophr Res* 13: 209–215, 1994.
 243. Stassen HH, Bridler R, Hagele S, Hergersberg M, Mehmam B, Schinzel A, Weisbrod M, and Scharfetter C. Schizophrenia and smoking: evidence for a common neurobiological basis? *Am J Med Genet* 96: 173–177, 2000.
 244. Steullet P, Cabungcal JH, Kulak A, Kraftsik R, Chen Y, Dalton TP, Cuenod M, and Do KQ. Redox dysregulation affects the ventral but not dorsal hippocampus: impairment of parvalbumin neurons, gamma oscillations, and related behaviors. *J Neurosci* 30: 2547–2558, 2010.
 245. Steullet P, Lavoie S, Kraftsik R, Guidi R, Gysin R, Cuenod M, and Do KQ. A glutathione deficit alters dopamine modulation of L-type calcium channels via D2 and ryanodine receptors in neurons. *Free Radic Biol Med* 44: 1042–1054, 2008.
 246. Strassnig M, Brar JS, and Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. *Schizophr Bull* 29: 393–397, 2003.
 247. Strauss JS and Carpenter WT Jr. Prediction of outcome in schizophrenia. III. Five-year outcome and its predictors. *Arch Gen Psychiatry* 34: 159–163, 1977.
 248. Strazzullo P and Puig JG. Uric acid and oxidative stress: relative impact on cardiovascular risk? *Nutr Metab Cardiovasc Dis* 17: 409–414, 2007.
 249. Suboticanec K, Folnegovic-Smalc V, Korbar M, Mestrovic B, and Buzina R. Vitamin C status in chronic schizophrenia. *Biol Psychiatry* 28: 959–966, 1990.
 250. Suzuki E, Nakaki T, Nakamura M, and Miyaoka H. Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia. *J Psychiatry Neurosci* 28: 288–292, 2003.
 251. Suzuki K. Chemistry and metabolism of brain lipids. In: *Basic Neurochemistry* (3rd edition), edited by Siegel GJ, Albers RW, Agranoff BW, and Katzman R. Boston, MA: Little, Brown & Co., 1981, pp. 355–370.
 252. Tandon R, Nasrallah HA, and Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. *Schizophr Res* 110: 1–23, 2009.
 253. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, and Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. *Arch Med Res* 35: 401–405, 2004.
 254. Tashiro T, Yamamori H, Takagi K, Hayashi N, Furukawa K, and Nakajima N. N-3 versus n-6 polyunsaturated fatty acids in critical illness. *Nutrition* 14: 551–553, 1998.
 255. Thorns V, Hansen L, and Masliah E. nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer’s disease. *Exp Neurology* 150: 14–20, 1998.
 256. Tien AY and Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. *Arch Gen Psychiatry* 49: 37–46, 1992.
 257. Toncev G, Milicic B, Toncev S, and Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. *Eur J Neurol* 9: 221–226, 2002.
 258. Torrey EF and Yolken RH. The schizophrenia-rheumatoid arthritis connection, infectious, immune, or both? *Brain Behav Immun* 15: 401–410, 2001.
 259. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, and Tezcan E. Total antioxidant response in patients with schizophrenia. *Psychiatry Clin Neurosci* 60: 458–464, 2006.
 260. van der Veen RC, Hinton DR, Incardonna F, and Hofman FM. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. *J Neuroimmunol* 77: 1–7, 1997.
 261. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, and Yao JK. Elevated interleukin-6 in schizophrenia. *Psychiatry Res* 87: 129–136, 1999.
 262. van Os J and Kapur S. Schizophrenia. *Lancet* 374: 635–645, 2009.
 263. Vaughan K and McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial. *Aust N Z J Psychiatry* 33: 84–88, 1999.
 264. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, and Shetty K. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naïve schizophrenia. *Am J Psychiatry* 164: 1557–1560, 2007.
 265. Villemain F, Chate-noud L, Galinowski A, Homo-Delar-che F, Genestet D, Loo H, Zarifarain E, and Bach JF. Aberrant T-cell-mediated immunity in untreated schizophrenic patients: deficient Interleukin-2 production. *Am J Psychiatry* 146: 609–616, 1989.
 266. Vinogradov S, Gottesman II, Moises HW, and Nicol S. Negative association between schizophrenia and rheumatoid arthritis. *Schizophr Bull* 17: 669–678, 1991.
 267. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, Erel O, Herken H. A defect in the antioxidant defense system in Schizophrenia. *Neuropsychobiology* 60: 87–93, 2009.
 268. Vitek L, Lenicek M, Jirsa M, Novotna M, Novotny L, Eberova J, Petrasek J, and Jirsa M. Serum bilirubin levels and UGT1A1 promoter variations in patients with schizophrenia. *Psychiatry Res* 178: 449–450, 2010.
 269. Wang JF, Shao L, Sun X, and Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. *Bipolar Disord* 11: 523–529, 2009.
 270. Waring WS, Webb DJ, and Maxwell SR. Uric acid as a risk factor for cardiovascular disease. *Quart J Med* 93: 707–713, 2000.
 271. Wayner DDM, Burton GW, Ingold KU, Barclay LRC, and Locke SJ. The relative contribution of vitamins E, urate, ascorbate and proteins to the total peroxy radical-trapping antioxidant activity of human blood plasma. *Biochim Biophys Acta* 924: 408–419, 1987.
 272. Wilke I, Arolt V, Rothermundt M, Weitzsch CH, Hornberg M, and Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. *Eur Arch Psychiatry Clin Neurosci* 246: 279–284, 1996.
 273. Williamson P, Drost D, Stanley J, Carr T, Morrison S, and Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. *Arch Gen Psychiatry* 48: 578, 1991.
 274. Wolfner A, Abuja PM, Schauenstein K, and Liebmann PM. N-acetylserotonin is a better extra- and intracellular antioxidant than melatonin. *FEBS Lett* 449: 206–210, 1999.

275. Wong C-T, Tsoi W-F, and Saha N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. *Schizophr Res* 22: 165–171, 1996.
276. Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, McGorry PD, and Pantelis C. Medial temporal lobe glutathione concentration in first episode psychosis: a ¹H-MRS investigation. *Neurobiol Dis* 33: 354–357, 2009.
277. Xing G, Chavko M, Zhang LX, Yang S, and Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. *Schizophr Res* 58: 21–30, 2002.
278. Yamada K, Kanba S, Anamizu S, Ohnishi K, Ashikari I, Yagi G, and Asai M. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. *Psychol Med* 27: 1223–1225, 1997.
279. Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu SS, Herken H, Savas HA, Koylu A, and Akyol O. Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? *Neuropsychobiology* 47: 61–65, 2003.
280. Yao JK and Cheng P. Determination of multiple redox-active compounds by high-performance liquid chromatography with coulometric multi-electrode array system. *J Chromatogr B* 810: 93–100, 2004.
281. Yao JK and Reddy RD. Metabolic investigation in psychiatric disorders. *Mol Neurobiology* 31: 193–203, 2005.
282. Yao JK and van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. *Int Rev Neurobiol* 59: 297–326, 2004.
283. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, and Kaddurah-Daouk R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. *Mol Psychiatry* 15: 938–953, 2010.
284. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, and Kaddurah-Daouk R. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. *PLoS One* 5: e9508, 2010.
285. Yao JK, Leonard S, and Reddy R. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. *Schizophr Res* 42: 7–17, 2000.
286. Yao JK, Leonard S, and Reddy RD. Altered glutathione redox state in schizophrenia. *Disease Markers* 22, 83–93, 2006.
287. Yao JK, Leonard S, and Reddy RD. Increased nitric oxide radicals in postmortem brains from schizophrenic patients. *Schizophr Bull* 30: 923–934, 2004.
288. Yao JK, Reddy R, and van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. *Biol Psychiatry* 45: 1512–1515, 1999.
289. Yao JK, Reddy R, and van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. *Psychiatry Res* 80: 29–39, 1998.
290. Yao JK, Reddy R, McElhinny LG, and van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. *J Psychiatry Res* 32: 385–391, 1998.
291. Yao JK, Reddy R, McElhinny LG, and van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. *Schizophr Res* 32: 1–8, 1998.
292. Yao JK, Reddy RD, and van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. *Psychiatry Res* 97: 137–151, 2000.
293. Yao JK, Reddy RD, and van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. *CNS Drugs* 15: 287–310, 2001.
294. Yao JK, Stanley JA, Reddy RD, Keshavan MS, and Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and *in vivo* membrane phospholipid metabolites. *Biol Psychiatry* 52: 823–830, 2002.
295. Yao JK, van Kammen DP, and Gurklis J. Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia. *Psychiatry Res* 60: 11–21, 1996.
296. Yao JK, van Kammen DP, and Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. *Schizophr Res* 13: 217–226, 1994.
297. Yao JK, van Kammen DP, Reddy RD, and Kelley ME. Superoxide dismutase and negative symptoms in schizophrenia. *Biol Psychiatry* 43: 123S–124S, 1998.
298. Yao JK, Yasaei P, and van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. *Prostaglandins Leukot Essent Fatty Acids* 46: 39–46, 1992.
299. Yao JK. Abnormalities of fatty acid metabolism in red cells, platelets and brain in schizophrenia. In: *Phospholipid Spectrum Disorders in Psychiatry and Neurology* (2nd edition), edited by Peet M, Glen I, and Horrobin DF. Lancashire, UK: Marius Press, 2003, pp. 193–212.
300. Zhang F and Dryhurst G. Effects of l-cysteine on the oxidative chemistry of dopamine: new reaction pathways of potential relevance to ideopathic Parkinson's disease. *J Med Chem* 37: 1084–1098, 1994.
301. Zhang XY, Chen DC, Xiu MH, Wang F, Qi LY, Sun HQ, Chen S, He SC, Wu GY, Haile CN, Kosten TA, Lu L, and Kosten TR. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. *Schizophr Res* 113: 151–157, 2009.
302. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, and Zhou DF. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. *Schizophr Res* 81: 291–300, 2006.
303. Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, and Kosten TR. Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. *J Clin Psychiatry* 68: 754–760, 2007.
304. Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, and Kosten TR. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. *Neuropsychopharmacology* 32: 2020–2024, 2007.
305. Zhang XY, Zhou DF, Cao LY, Zhang PY, and Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. *Psychiatry Res* 117: 85–88, 2003.
306. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen DC, Xiu MH, Wang F, Wu GY, Lu L, Kosten TA, and Kosten TR. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. *Psychopharmacology (Berl)* 204: 177–184, 2009.
307. Zhang ZJ, Ramchand CN, Ramchand R, Milner E, Telang SD, and Peet M. Glutathione peroxidase (GSHPx) activity in plasma and fibroblasts from schizophrenics and control. *Biol Psychiatry* 29: 103–104, 1998.
308. Zoroglu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI, and Akyol O. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. *J Psychiatry Res* 36: 309–315, 2002.

Address correspondence to:
Dr. Jeffrey K. Yao
 VA Pittsburgh Healthcare System (151U-H)
 Medical Research Service
 7180 Highland Drive
 Pittsburgh, PA 15206
 E-mail: jkyao@pitt.edu

Date of first submission to ARS Central, August 24, 2010;
 date of final revised submission, November 26, 2010; date of
 acceptance, December 2, 2010.

Abbreviations Used

2-AG = 2-arachidonoyl glycerol
 AA = arachidonic acid
 AODS = antioxidant defense system
 ATP = adenosine triphosphate
 BHPR = Bunney-Hamburg psychosis ratings
 CAT = catalase
 CSF = cerebrospinal fluid
 DA = deaminase
 DAG = diacylglycerol
 DHA = docosahexaenoic acid
 eNOS = endothelial nitric oxide synthase
 FENNS = first-episode neuroleptic-naïve patient
 with schizophrenia
 GAP = growth-associated protein
 GSH = glutathione
 GSH-Px = glutathione peroxidase
 GSH-R = glutathione reductase
 GSSG = oxidized glutathione
 H₂O₂ = hydrogen peroxide

Hx = hypoxanthine
 IL = interleukin
 iNOS = inducible nitric oxide synthase
 IPPs = inositol polyphosphates
 MAO = monoamine oxidase
 MDA = malondialdehyde
 MRS = magnetic resonance spectroscopy
 NMDA = N-methyl-D-aspartate
 nNOS = neuronal nitric oxide synthase
 NO = nitric oxide
 NOS = nitric oxide synthase
 OH• = hydroxyl radical
 PC = phosphatidylcholine
 PCr = phosphocreatine
 PDEs = phosphodiesterases
 PE = phosphatidylethanolamine
 Pi = inorganic phosphate
 PI = phosphatidylinositol
 PLA₂ = phospholipase A₂
 PLC = phospholipase C
 PMEs = phosphmonoesters
 PS = phosphatidylserine
 PUFAs = polyunsaturated fatty acids
 RBC = red blood cell
 ROS = reactive oxygen species
 SANS = Scale for the Assessment of Negative
 Symptoms
 SOD = superoxide dismutase
 SZ = schizophrenia
 TAS = total antioxidant status
 UA = uric acid
 Xan = xanthine
 Xant = xanthosine
 XO = xanthine oxidase

